var title_f15_20_15680="Nonbleeding esophageal varices";
var content_f15_20_15680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F87066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F87066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal varices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic images from a patient with esophageal varices. Varices may or may not have stigmata of bleeding. These varices are large but do not have clear stigmata of bleeding, such as red wale signs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15680=[""].join("\n");
var outline_f15_20_15680=null;
var title_f15_20_15681="Child ecchymoses";
var content_f15_20_15681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ecchymoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Leslie Raffini, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15681=[""].join("\n");
var outline_f15_20_15681=null;
var title_f15_20_15682="Scarlet fever rash - Pastia's lines";
var content_f15_20_15682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Scarlet fever rash - Pastia's lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rash of scarlet fever is marked in the skin folds of the inguinal, axillary, antecubital, and abdominal areas and about pressure points. It often exhibits a linear petechial character in the antecubital fossae and axillary folds, known as Pastia's lines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15682=[""].join("\n");
var outline_f15_20_15682=null;
var title_f15_20_15683="Electroanatomic map MI";
var content_f15_20_15683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical electroanatomic map of infarcted myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The electronatomic map of a patient with a myocardial infarction shows large regions of abnormal electromechanical activity and reduced local shortening (red, abnormally contracting regions with values &lt;4 percent). In contrast, a region in which function remains unhindered is a color-coded blue/purple, normal contractile function &gt;12 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology (Journal of the American College of Cardiology, 2001, 37:1590-7).",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15683=[""].join("\n");
var outline_f15_20_15683=null;
var title_f15_20_15684="Chapter 3C: Secretory pathways in proximal tubule";
var content_f15_20_15684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 3C: Secretory pathways in proximal tubule",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15684/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15684/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15684/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15684/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15684/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15684/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15684/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/20/15684/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2003.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their reabsorptive functions, the proximal tubular cells secrete hydrogen ions and organic cations and anions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The last two processes occur primarily in the S2 segment (",
"    <a class=\"graphic graphic_figure graphicRef58220 \" href=\"UTD.htm?22/29/23006\">",
"     figure 1",
"    </a>",
"    ), which has the highest number of secretory pumps [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In general, tubular secretion occurs in three steps: movement of the organic solute from the peritubular capillary into the interstitium by diffusion; transport of the solute into the cell across the basolateral membrane; and secretion from the cell into the lumen across the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ORGANIC CATION SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which these processes may occur can be illustrated from studies with organic cations, examples of which include creatinine and drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef52320 \" href=\"UTD.htm?21/16/21773\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It is likely that passive forces play a role in cell entry across the basolateral membrane, since the cation concentration in the extracellular fluid is higher than that in the cell and there is a cell interior negative potential. This process appears to occur by facilitated diffusion via cation-cation countertransport proteins, with substantial intracellular sequestration of organic cations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. Overall, the characterization of the transporter proteins and a knowledge of the specific concentration gradients is required to best understand the movement of organic cations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large number of specific transporters expressed on the basolateral membrane have been isolated and cloned [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/9\">",
"     9",
"    </a>",
"    ]. These include a polyspecific cation transporter, named OCT1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/10\">",
"     10",
"    </a>",
"    ]. This transporter is sodium-independent and potential-dependent and can transport a wide variety of cations, including choline, dopamine and acetylcholine.",
"   </p>",
"   <p>",
"    For most organic cations, subsequent secretion across the luminal membrane appears to principally occur in parallel with the Na+-H+ antiporter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/6\">",
"     6",
"    </a>",
"    ]. The latter leads to a rise in the tubular fluid hydrogen concentration that allows secretion of the organic cation to be linked to the favorable inward H+ gradient by different H+-cation exchangers (",
"    <a class=\"graphic graphic_figure graphicRef52320 \" href=\"UTD.htm?21/16/21773\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/7,11,12\">",
"     7,11,12",
"    </a>",
"    ]. Notice that the energy for each of these steps is again provided indirectly by the Na+-K+-ATPase pump. The low cell Na+ concentration drives the Na+-H+ antiporter, and the high cell K+ concentration results in passive K+ diffusion out of the cell and the generation of cell negativity.",
"   </p>",
"   <p>",
"    The organic cations tend to compete for common secretory mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. As a result, the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , for example, can diminish the secretion of creatinine, reversibly raising the plasma creatinine concentration without any decline in the glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/13\">",
"     13",
"    </a>",
"    ]. This effect may also be useful clinically by making the creatinine clearance a more accurate estimate of the glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21368?source=see_link&amp;anchor=H2#H2\">",
"     \"Chapter 2E: Clinical evaluation of the renal circulation\", section on 'Use and limitations of creatinine clearance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ORGANIC ANION SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organic anions, both endogenous (urate, hippurate, ketoacid anions) and exogenous (penicillins, cephalosporins, salicylates, diuretics, radiocontrast media) compete for different secretory pathways. The mechanism by which this occurs is not well understood, but, as described elsewhere for urate, anion exchangers at the basolateral membrane and perhaps the luminal membrane appear to play an essential role (",
"    <a class=\"graphic graphic_figure graphicRef72770 \" href=\"UTD.htm?25/8/25741\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/2,3,6,16,17\">",
"     2,3,6,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36905?source=see_link&amp;anchor=H10#H10\">",
"     \"Chapter 3B: Primacy of sodium transport in proximal function\", section on 'Uric acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Energy for organic anion transport is provided by the Na+-K+-ATPase pump, which maintains a low cell Na+ concentration, thereby creating a concentration gradient favoring passive Na+ entry into the cell. Citric acid cycle intermediates (particularly alpha-ketoglutarate) can enter the cell by cotransport with sodium across the basolateral membrane (via the sodium-dicarboxylate symporter [NaDC-3]) and are also produced within the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/17\">",
"     17",
"    </a>",
"    ]. The intracellular accumulation of alpha-ketoglutarate creates a favorable outward gradient for this compound that can then be used to drive the entry of organic anions into the cell via organic anion transporter (OAT) 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of OATs in the basolateral membrane have been characterized",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cloned. OAT 1 has specificity for organic anions, including para-aminohippurate and alpha-ketoglutarate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/18\">",
"     18",
"    </a>",
"    ]. Additional basolateral transporters include the multidrug resistance transport-associated protein, and OATs 2 and 3. All three OATs may contribute to urate entry into the cell, while OAT3 may be of greatest importance for transporting large organic anions, such as drugs and steroid hormones.",
"   </p>",
"   <p>",
"    Organic anions that enter the cell across the basolateral membrane are then secreted into the tubular lumen. Secretion into the lumen may then occur by several mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Facilitated diffusion via OAT 1 in the luminal membrane, since the cell interior negative potential creates a favorable electrical gradient.",
"     </li>",
"     <li>",
"      By anion exchange for filtered urate via the URAT1 exchanger that mediates urate reabsorption.",
"     </li>",
"     <li>",
"      Possibly by active transport.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Competition for these pathways can be important clinically. As an example, fasting subjects frequently develop hyperuricemia. It is thought that this is secondary to the ketonemia of fasting, which could diminish urate secretion. Organic anion secretion can also be inhibited by the drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/16\">",
"     16",
"    </a>",
"    ]. This property is useful in selected patients, as probenecid has been given in conjunction with penicillin therapy. By reducing penicillin secretion (and excretion), higher blood levels of the antibiotic can be achieved.",
"   </p>",
"   <p>",
"    The fact that these pathways are relatively nonspecific and are able to secrete foreign substances makes them well adapted for a major role in the",
"    <strong>",
"     elimination of drugs and chemicals",
"    </strong>",
"    from the body. This is particularly important for those agents that are highly albumin-bound and therefore cannot be excreted by glomerular filtration. Albumin-binding promotes proximal secretion in two ways. First, binding appears to be required for secretion, which does not occur with free organic anions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/19\">",
"     19",
"    </a>",
"    ]. Second, binding facilitates the urinary excretion of these compounds by maximizing their rate of delivery to the secretory sites in the kidney. Albumin and other large proteins cannot easily cross the peripheral capillary membranes; as a result, protein-bound compounds are largely restricted to the vascular space, with limited access to the interstitium or the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other transport processes may be involved in the renal handling of organic solutes. In particular, these substances can undergo passive reabsorption or secretion depending upon the urine pH. Salicylic acid, for example, exists both as the intact acid and the organic anion:",
"   </p>",
"   <p>",
"    Salicylic acid &nbsp; &lt;&mdash;&gt; &nbsp;H+ &nbsp;+ &nbsp;salicylate-",
"   </p>",
"   <p>",
"    The intact acid, but not the organic anion, can freely diffuse across cell membranes because it is nonpolar. This difference makes salicylate excretion",
"    <strong>",
"     pH-dependent",
"    </strong>",
"    . Raising the urine pH (which lowers the free H+ concentration) will shift the above reaction to the right. The ensuing fall in the urinary salicylic acid concentration will minimize the back diffusion of secreted salicylic acid out of the tubular lumen, thereby increasing total drug excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15684/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, elevating the urine pH is an important component of the treatment of salicylate intoxication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This text is continued elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link\">",
"     \"Chapter 4A: Cell model for loop of Henle transport\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/1\">",
"      Grantham JJ. Studies of organic anion and cation transport in isolated segments of proximal tubules. Kidney Int 1982; 22:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/2\">",
"      Burckhardt G, Ullrich KJ. Organic anion transport across the contraluminal membrane--dependence on sodium. Kidney Int 1989; 36:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/3\">",
"      Pritchard JB, Miller DS. Renal secretion of organic anions and cations. Kidney Int 1996; 49:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/4\">",
"      Woodhall PB, Tisher CC, Simonton CA, Robinson RR. Relationship between para-aminohippurate secretion and cellular morphology in rabbit proximal tubules. J Clin Invest 1978; 61:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/5\">",
"      Shimomura A, Chonko AM, Grantham JJ. Basis for heterogeneity of para-aminohippurate secretion in rabbit proximal tubules. Am J Physiol 1981; 240:F430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/6\">",
"      Pritchard JB, Miller DS. Comparative insights into the mechanisms of renal organic anion and cation secretion. Am J Physiol 1991; 261:R1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/7\">",
"      McKinney TD, Kunnemann ME. Cimetidine transport in rabbit renal cortical brush-border membrane vesicles. Am J Physiol 1987; 252:F525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/8\">",
"      Dantzler WH, Wright SH, Chatsudthipong V, Brokl OH. Basolateral tetraethylammonium transport in intact tubules: specificity and trans-stimulation. Am J Physiol 1991; 261:F386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/9\">",
"      Koepsell H, Busch A, Gorboulev V, Arndt P. Structure and Function of Renal Organic Cation Transporters. News Physiol Sci 1998; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/10\">",
"      Zhang L, Dresser MJ, Chun JK, et al. Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem 1997; 272:16548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/11\">",
"      Miyamoto Y, Tiruppathi C, Ganapathy V, Leibach FH. Multiple transport systems for organic cations in renal brush-border membrane vesicles. Am J Physiol 1989; 256:F540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/12\">",
"      Ott RJ, Hui AC, Yuan G, Giacomini KM. Organic cation transport in human renal brush-border membrane vesicles. Am J Physiol 1991; 261:F443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/13\">",
"      Rocci ML Jr, Vlasses PH, Ferguson RK. Creatinine serum concentrations and H2-receptor antagonists. Clin Nephrol 1984; 22:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/14\">",
"      Hilbrands LB, Artz MA, Wetzels JF, Koene RA. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 1991; 40:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/15\">",
"      van Acker BA, Koomen GC, Koopman MG, et al. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 1992; 340:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/16\">",
"      Ullrich KJ, Rumrich G. Contraluminal transport systems in the proximal renal tubule involved in secretion of organic anions. Am J Physiol 1988; 254:F453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/17\">",
"      Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 2003; 146:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/18\">",
"      Sekine T, Watanabe N, Hosoyamada M, et al. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 1997; 272:18526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/19\">",
"      Besseghir K, Mosig D, Roch-Ramel F. Facilitation by serum albumin of renal tubular secretion of organic anions. Am J Physiol 1989; 256:F475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/20\">",
"      Inoue M, Koyama H, Nagase S, Morino Y. Renal secretion of phenolsulfonphthalein: analysis of its vectorial transport in normal and mutant analbuminemic rats. J Lab Clin Med 1985; 105:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15684/abstract/21\">",
"      Chatton JY, Besseghir K, Roch-Ramel F. Salicylic acid permeability properties of the rabbit cortical collecting duct. Am J Physiol 1990; 259:F613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7269 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15684=[""].join("\n");
var outline_f15_20_15684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ORGANIC CATION SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ORGANIC ANION SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7269|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/29/23006\" title=\"figure 1\">",
"      Proximal tubule segments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/16/21773\" title=\"figure 2\">",
"      Organic cation secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/8/25741\" title=\"figure 3\">",
"      Proximal uric acid secretion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21368?source=related_link\">",
"      Chapter 2E: Clinical evaluation of the renal circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36905?source=related_link\">",
"      Chapter 3B: Primacy of sodium transport in proximal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_20_15685="Sebaceous cell carcinoma eyelid";
var content_f15_20_15685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sebaceous carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodules that originally resemble chalazia then cause loss of lashes and destruction of the meibomian gland orifices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15685=[""].join("\n");
var outline_f15_20_15685=null;
var title_f15_20_15686="Classification of pancreatic cysts";
var content_f15_20_15686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of pancreatic cysts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15686/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15686/contributors\">",
"     Asif Khalid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15686/contributors\">",
"     Kevin McGrath, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15686/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15686/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15686/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15686/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/20/15686/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cysts are being diagnosed with increasing frequency because of the widespread use of cross-sectional imaging. As an example, pancreatic cysts were detected in 1.2 percent of more than 24,000 patients at a major medical center who underwent abdominal imaging with computed tomography or magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatic cysts can either be neoplastic (eg, intraductal papillary mucinous neoplasms) or non-neoplastic. Accurate cyst categorization is important since non-neoplastic cysts require treatment only if symptomatic, whereas some of the pancreatic cystic neoplasms have significant malignant potential and should be resected.",
"   </p>",
"   <p>",
"    This topic will review the classification of pancreatic cysts. An overview of pancreatic cystic neoplasms and issues related to pancreatic pseudocysts and intraductal papillary mucinous neoplasms of the pancreas are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link\">",
"       \"Pancreatic cystic neoplasms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"       \"Diagnosis and management of pseudocysts of the pancreas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=see_link\">",
"       \"Endoscopic management of pseudocysts of the pancreas: Efficacy and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27655?source=see_link\">",
"       \"Endoscopic management of pseudocysts of the pancreas: Technique\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF PANCREATIC CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic lesions of the pancreas can be divided pathologically into pseudocysts, non-neoplastic pancreatic cysts, and pancreatic cystic neoplasms (PCNs). Rarely, solid pancreatic tumors may also present as a pancreatic cyst (eg, islet cell tumor). Most pancreatic cysts are detected incidentally when abdominal imaging is performed for some other indication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/1\">",
"     1",
"    </a>",
"    ]. PCNs account for more than half of pancreatic cysts, even in patients with a history of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatic cystic lesions can be an isolated finding, or they can be associated with an underlying disorder such as von Hippel-Lindau disease or polycystic kidney disease. In a study of 158 consecutive patients with von Hippel-Lindau disease, 77 percent had a pancreatic abnormality, including 70 percent with cysts, 9 percent with serous cystadenomas, and 9 percent with neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancreatic cysts are seen in 7 to 10 percent of patients with autosomal dominant polycystic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link&amp;anchor=H10#H10\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\", section on 'Pancreatic cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PSEUDOCYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic pseudocysts are lined by fibrous tissue and granulation tissue. The lack of an epithelial lining distinguishes pseudocysts from true cystic lesions of the pancreas. Pseudocysts may be single or multiple, small or large, and located either within or outside of the pancreas. Most pseudocysts communicate with the pancreatic ductal system and contain high concentrations of digestive enzymes.",
"   </p>",
"   <p>",
"    Pseudocysts of the pancreas result from pancreatic inflammation and necrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71785 \" href=\"UTD.htm?21/1/21524\">",
"     image 1",
"    </a>",
"    ). They comprise 15 to 30 percent of pancreatic cysts overall [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/4\">",
"     4",
"    </a>",
"    ], and close to 50 percent of pancreatic cysts in patients with a history of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/2\">",
"     2",
"    </a>",
"    ]. Given that half of the cysts in patients with a history of acute pancreatitis are PCNs, a cystic lesion in a patient with a history of acute pancreatitis should only be diagnosed as a pseudocyst if the patient had initial imaging that showed the absence of a cyst, but then had follow-up imaging (within a few months of the episode) that demonstrated a new cyst with radiographic characteristics consistent with a pseudocyst. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link&amp;anchor=H8#H8\">",
"     \"Pancreatic cystic neoplasms\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NON-NEOPLASTIC PANCREATIC CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-neoplastic pancreatic cysts (NNPCs) include a variety of very rare cysts that are often asymptomatic and do not require resection. These include true cysts, retention cysts, mucinous non-neoplastic cysts, and lymphoepithelial cysts. They are typically diagnosed after surgical resection of a lesion that was thought to be a pancreatic cystic neoplasm (PCN) preoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     True cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only a few cases reported of true cysts or \"benign epithelial cysts\" of the pancreas. These cystic lesions with a cuboidal epithelial lining have an unclear natural history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Retention cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retention cysts are small dilated pancreatic duct side branches arising due to obstruction (eg, from pancreatic intraepithelial neoplasia or from inspissated protein debris seen in association with chronic pancreatitis or cystic fibrosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mucinous non-neoplastic cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucinous non-neoplastic cysts have only recently been described and are exceedingly difficult to differentiate from PCNs. Like PCNs, mucinous non-neoplastic cysts are lined with a mucinous lining, but they lack any neoplastic features (eg, atypia) or ductal communication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/5\">",
"     5",
"    </a>",
"    ]. These lesions have an unclear natural history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lymphoepithelial cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoepithelial cysts (LEC) are rare, benign, and usually asymptomatic cystic lesions. Often described as peripancreatic, these lesions are lined by mature keratinizing squamous epithelium surrounded by a distinct layer of lymphoid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/6\">",
"     6",
"    </a>",
"    ]. Endoscopic ultrasound with fine needle aspiration (EUS-FNA) may be required to differentiate an LEC from a PCN. FNA cytology usually reveals characteristic epithelial cells and small, mature lymphocytes in a background of keratinaceous debris, anucleate squamous cells, and multinucleated histiocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/7\">",
"     7",
"    </a>",
"    ]. Resection is recommended in symptomatic cases, but not for asymptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PANCREATIC CYSTIC NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying pancreatic cystic neoplasms (PCNs) is important, since some have malignant potential. PCNs are categorized using the WHO histological classification [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69594 \" href=\"UTD.htm?5/20/5452\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are four subtypes of PCNs:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serous cystic tumors",
"     </li>",
"     <li>",
"      Mucinous cystic neoplasms (MCNs)",
"     </li>",
"     <li>",
"      Intraductal papillary mucinous neoplasms (IPMNs)",
"     </li>",
"     <li>",
"      Solid pseudopapillary neoplasms (SPNs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The key demographic and clinical features of PCNs are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef57759 \" href=\"UTD.htm?38/0/38925\">",
"     table 2",
"    </a>",
"    ). Each of the subtypes has benign and malignant forms.",
"   </p>",
"   <p>",
"    The relative frequencies of the different PCNs were examined in a retrospective series of 851 patients undergoing surgical resection for a cystic neoplasm of the pancreas between 1978 and 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/10\">",
"     10",
"    </a>",
"    ]. Intraductal papillary mucinous neoplasms accounted for 38 percent of lesions, mucinous cystic neoplasms for 23 percent, serous cystic tumors for 16 percent, and solid pseudopapillary neoplasms for 3 percent. When only the 376 patients who had surgery between 2005 and 2011 were considered, 49 percent had intraductal papillary mucinous neoplasms, 16 percent had mucinous cystic neoplasms, 12 percent had serous cystic tumors, and 5 percent had solid pseudopapillary neoplasms. &nbsp;However, this series is subject to referral bias, as it only evaluated resected PCNs. Most branch duct IPMNs and serous cystadenomas do not require resection; thus the relative frequency of these lesions may have been underestimated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serous cystic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most serous cystic tumors are serous cystadenomas, which are benign neoplasms lined by glycogen-rich cells that originate from pancreatic centro-acinar cells (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66608 \" href=\"UTD.htm?21/19/21810\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61511 \" href=\"UTD.htm?8/19/8503\">",
"     picture 1",
"    </a>",
"    ). These lesions can arise anywhere in the pancreas and are most commonly diagnosed in women over the age 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Varieties include microcystic serous cystadenomas, which are composed of multiple small cystic spaces (",
"    <a class=\"graphic graphic_picture graphicRef73288 graphicRef82546 graphicRef71673 \" href=\"UTD.htm?37/27/38330\">",
"     picture 2A-C",
"    </a>",
"    ), and oligocystic serous cystadenomas, which are composed of fewer, larger cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The oligocystic variant can be difficult to distinguish from an MCN or branch duct IPMN, which can have a similar appearance. Unless symptomatic, these can be followed conservatively since malignant degeneration is exceedingly rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link&amp;anchor=H18#H18\">",
"     \"Pancreatic cystic neoplasms\", section on 'Malignant potential and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mucinous cystic neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucinous cystic neoplasms (MCNs) (",
"    <a class=\"graphic graphic_picture graphicRef58137 graphicRef66804 \" href=\"UTD.htm?20/14/20713\">",
"     picture 3A-B",
"    </a>",
"    ) occur exclusively in women and are most commonly discovered after the age of 40 years. MCNs exhibit variable cellular atypia and secrete mucin similar to IPMNs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In contrast to IPMNs, MCNs demonstrate ovarian-like stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/19\">",
"     19",
"    </a>",
"    ], typically arise in the pancreatic tail or body (",
"    <a class=\"graphic graphic_picture graphicRef52386 \" href=\"UTD.htm?15/9/15509\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/18\">",
"     18",
"    </a>",
"    ], and do not communicate with the pancreatic duct. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Intraductal papillary mucinous neoplasms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Due to the risk of malignancy developing, resection is recommended in appropriate candidates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link&amp;anchor=H18#H18\">",
"     \"Pancreatic cystic neoplasms\", section on 'Malignant potential and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intraductal papillary mucinous neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraductal papillary mucinous neoplasms (IPMNs) are mucin-producing papillary neoplasms of the pancreatic ductal system that exhibit variable cellular atypia and cause dilation of the pancreatic ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/20\">",
"     20",
"    </a>",
"    ]. IPMNs have an equal sex distribution, with incidence peaking over the age of 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IPMNs may involve the main pancreatic duct (main duct IPMN) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51921 \" href=\"UTD.htm?2/19/2354\">",
"     image 3",
"    </a>",
"    ), its side branches (branch duct IPMN), or both (mixed type IPMN) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66204 \" href=\"UTD.htm?10/12/10432\">",
"     image 4",
"    </a>",
"    ). They are often multifocal or diffuse, and can extend microscopically from the clinically apparent lesions.",
"   </p>",
"   <p>",
"    The characteristic pathologic features include the diffuse or segmental dilation of the pancreatic duct without stricturing, the intraductal expansion of mucin-producing ductal cells (which may be flat or project into the lumen), and the dilation of either one or both pancreatic orifices, through which there is a copious secretion of mucus (",
"    <a class=\"graphic graphic_picture graphicRef52643 \" href=\"UTD.htm?18/34/18976\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Histologically, the columnar mucin-producing cells can be hyperplastic or dysplastic. They can be further classified based upon the degree of dysplasia exhibited by the epithelial cells as adenoma (mild dysplasia), borderline (moderate dysplasia), or carcinoma (high grade dysplasia), with or without invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management involves a combination of surveillance and resection depending upon the risk of malignancy and patient-related factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5510671#H5510671\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Solid pseudopapillary neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid pseudopapillary neoplasms (SPNs) of the pancreas are rare neoplasms that typically occur in young women less than 35 years of age. They have also been called solid and papillary epithelial neoplasms, papillary cystic tumors of the pancreas, and solid and cystic tumors.",
"   </p>",
"   <p>",
"    SPNs are most commonly found in the body or tail of the pancreas and may contain both solid and cystic components and occasional calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76413 \" href=\"UTD.htm?27/8/27776\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63887 \" href=\"UTD.htm?38/40/39556\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15686/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Malignant potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant potential of pancreatic cystic neoplasms is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link&amp;anchor=H18#H18\">",
"     \"Pancreatic cystic neoplasms\", section on 'Malignant potential and management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5510693#H5510693\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Prognosis and surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CYSTIC DEGENERATION IN SOLID PANCREATIC TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic degeneration has been described in most solid pancreatic tumors, including endocrine tumors, ductal carcinoma, and acinar cell carcinoma. These lesions are managed similarly to the malignancies from which they arise. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic lesions of the pancreas may be divided pathologically into pseudocysts, non-neoplastic pancreatic cysts, and pancreatic cystic neoplasms (PCNs). In addition, solid tumors may develop cystic degeneration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of pancreatic cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are four subtypes of PCNs with varying degrees of malignant potential (",
"      <a class=\"graphic graphic_table graphicRef69594 \" href=\"UTD.htm?5/20/5452\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57759 \" href=\"UTD.htm?38/0/38925\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serous cystic tumors",
"     </li>",
"     <li>",
"      Mucinous cystic neoplasms (MCNs)",
"     </li>",
"     <li>",
"      Intraductal papillary mucinous neoplasms (IPMNs)",
"     </li>",
"     <li>",
"      Solid pseudopapillary neoplasms (SPNs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differentiating PCNs from non-neoplastic cysts and pseudocysts, as well as determining the subtype of PCN is important for assessing malignant potential. While serous cystadenomas have almost no malignant potential, the mucin producing PCNs (MCNs and IPMNs) and SPNs do. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Non-neoplastic pancreatic cysts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pancreatic cystic neoplasms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/1\">",
"      Spinelli KS, Fromwiller TE, Daniel RA, et al. Cystic pancreatic neoplasms: observe or operate. Ann Surg 2004; 239:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/2\">",
"      Fern&aacute;ndez-del Castillo C, Targarona J, Thayer SP, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003; 138:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/3\">",
"      Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000; 119:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/4\">",
"      Fasanella KE, McGrath K. Cystic lesions and intraductal neoplasms of the pancreas. Best Pract Res Clin Gastroenterol 2009; 23:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/5\">",
"      Kosmahl M, Egawa N, Schr&ouml;der S, et al. Mucinous nonneoplastic cyst of the pancreas: a novel nonneoplastic cystic change? Mod Pathol 2002; 15:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/6\">",
"      Ramsden KL, Newman J. Lymphoepithelial cyst of the pancreas. Histopathology 1991; 18:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/7\">",
"      Nasr J, Sanders M, Fasanella K, et al. Lymphoepithelial cysts of the pancreas: an EUS case series. Gastrointest Endosc 2008; 68:170.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, Aaltonen, LA, Hamilton, SR (Eds), IARC Press, Lyon, France 2000.",
"    </li>",
"    <li>",
"     Zamboni, G, Kloeppel, G, Hruban, RH, et, al. Mucinous cystic neoplasms of the pancreas. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, Aaltonen, LA, Hamilton, SR (Eds), IARC Press, Lyon, France 2000. p.234.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/10\">",
"      Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery 2012; 152:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/11\">",
"      Compagno J, Oertel JE. Microcystic adenomas of the pancreas (glycogen-rich cystadenomas): a clinicopathologic study of 34 cases. Am J Clin Pathol 1978; 69:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/12\">",
"      Pyke CM, van Heerden JA, Colby TV, et al. The spectrum of serous cystadenoma of the pancreas. Clinical, pathologic, and surgical aspects. Ann Surg 1992; 215:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/13\">",
"      Lundstedt C, Dawiskiba S. Serous and mucinous cystadenoma/cystadenocarcinoma of the pancreas. Abdom Imaging 2000; 25:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/14\">",
"      Brugge WR, Lauwers GY, Sahani D, et al. Cystic neoplasms of the pancreas. N Engl J Med 2004; 351:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/15\">",
"      Lewandrowski K, Warshaw A, Compton C. Macrocystic serous cystadenoma of the pancreas: a morphologic variant differing from microcystic adenoma. Hum Pathol 1992; 23:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/16\">",
"      Gouhiri M, Soyer P, Barbagelatta M, Rymer R. Macrocystic serous cystadenoma of the pancreas: CT and endosonographic features. Abdom Imaging 1999; 24:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/17\">",
"      Sarr MG, Carpenter HA, Prabhakar LP, et al. Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg 2000; 231:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/18\">",
"      Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999; 23:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/19\">",
"      Reddy RP, Smyrk TC, Zapiach M, et al. Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer. Clin Gastroenterol Hepatol 2004; 2:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/20\">",
"      D'Angelica M, Brennan MF, Suriawinata AA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004; 239:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/21\">",
"      Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004; 239:788.",
"     </a>",
"    </li>",
"    <li>",
"     Kloeppel G, Solcia E, Longnecker DS, et al. Histological typing of tumours of the exocrine pancreas. In: World Health Organization International Histological Classification of Tumours, Springer Verlag, New York 1996.",
"    </li>",
"    <li>",
"     Solcia EC, Kloppel G. Tumors of the pancreas, Fascicle 20. 3rd series ed, Armed Forces Institute of Pathology, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/24\">",
"      Master SS, Savides TJ. Diagnosis of solid-pseudopapillary neoplasm of the pancreas by EUS-guided FNA. Gastrointest Endosc 2003; 57:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15686/abstract/25\">",
"      Mergener K, Detweiler SE, Traverso LW. Solid pseudopapillary tumor of the pancreas: diagnosis by EUS-guided fine-needle aspiration. Endoscopy 2003; 35:1083.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5637 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15686=[""].join("\n");
var outline_f15_20_15686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF PANCREATIC CYSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PSEUDOCYSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NON-NEOPLASTIC PANCREATIC CYSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      True cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Retention cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mucinous non-neoplastic cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lymphoepithelial cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PANCREATIC CYSTIC NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serous cystic tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mucinous cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intraductal papillary mucinous neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Solid pseudopapillary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Malignant potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CYSTIC DEGENERATION IN SOLID PANCREATIC TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5637|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/1/21524\" title=\"diagnostic image 1\">",
"      Pancreatic pseudocyst 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/19/21810\" title=\"diagnostic image 2\">",
"      Serous cystadenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/19/2354\" title=\"diagnostic image 3\">",
"      CT IPMN parenchymal atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/12/10432\" title=\"diagnostic image 4\">",
"      MRCP mixed type IPMN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/8/27776\" title=\"diagnostic image 5\">",
"      Cystic lesion calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5637|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/19/8503\" title=\"picture 1\">",
"      Serous cystadenoma Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/17/36118\" title=\"picture 2A\">",
"      Serous cystadenoma Light I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/60/15303\" title=\"picture 2B\">",
"      Serous cystadenoma Light II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/28/15811\" title=\"picture 2C\">",
"      Serous cystadenoma PAS Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/9/4244\" title=\"picture 3A\">",
"      Mucinous neoplasm panc Gross I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/45/28373\" title=\"picture 3B\">",
"      Mucinous neoplasm panc Gross II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/9/15509\" title=\"picture 4\">",
"      Mucinous cystadenoma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/34/18976\" title=\"picture 5\">",
"      Papilla extruding mucus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/40/39556\" title=\"picture 6\">",
"      Pseudopapill neoplasm gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/20/5452\" title=\"table 1\">",
"      WHO classif panc cyst neopl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/0/38925\" title=\"table 2\">",
"      Clin features panc neoplasm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=related_link\">",
"      Diagnosis and management of pseudocysts of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=related_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Efficacy and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27655?source=related_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=related_link\">",
"      Pancreatic cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=related_link\">",
"      Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_20_15687="Telmisartan and hydrochlorothiazide: Drug information";
var content_f15_20_15687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Telmisartan and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/59/29621?source=see_link\">",
"    see \"Telmisartan and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Micardis&reg; HCT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Micardis&reg; Plus;",
"     </li>",
"     <li>",
"      Mylan-Telmisartan HCTZ;",
"     </li>",
"     <li>",
"      Telmisartan HCTZ;",
"     </li>",
"     <li>",
"      Teva-Telmisartan HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Replacement therapy: Combination product can be substituted for individual titrated agents. Initiation of combination therapy when monotherapy has failed to achieve desired effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients currently on telmisartan:",
"     </b>",
"     Initial dose if blood pressure is not currently controlled on monotherapy of 80 mg telmisartan: Telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily; may titrate up to telmisartan 160 mg/hydrochlorothiazide 25 mg if needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients currently on hydrochlorothiazide:",
"     </b>",
"     Initial dose if blood pressure is not currently controlled on monotherapy of 25 mg once daily: Telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily or telmisartan 80 mg/hydrochlorothiazide 25 mg once daily; may titrate up to telmisartan 160 mg/hydrochlorothiazide 25 mg if blood pressure remains uncontrolled after 2-4 weeks of therapy. Patients who develop hypokalemia while on hydrochlorothiazide 25 mg may be switched to telmisartan 80 mg/hydrochlorothiazide 12.5 mg.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F225122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Monitor renal function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F225123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F225124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment or biliary obstructive disorders: Initial: Telmisartan 40 mg/hydrochlorothiazide 12.5 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Micardis&reg; HCT:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40/12.5: Telmisartan 40 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     80/12.5: Telmisartan 80 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     80/25: Telmisartan 80 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Micardis&reg; Plus: 80/25: Telmisartan 80 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9614176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; combination product should not be used for initial therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to telmisartan, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with telmisartan/hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration of renal function and/or increases in serum creatinine, particularly in patients dependent on renin-angiotensin-aldosterone system; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients who have biliary obstructive disorders or hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use telmisartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use telmisartan with caution with pre-existing renal insufficiency and severe renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective); may precipitate azotemia; discontinue or consider withholding if renal impairment occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction; concurrent use with ramipril is not recommended. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F225131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Telmisartan may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramipril: Telmisartan may increase the serum concentration of Ramipril. Concentrations of the active metabolite, ramiprilat, may also be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (may potentiate orthostatic hypotension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid herbs with hypertensive properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice); may diminish the antihypertensive effect of telmisartan. Avoid herbs with hypotensive properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse); may enhance the hypotensive effect of telmisartan/hydrochorothiazide.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F225111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if telmisartan is excreted in human breast milk, use during breast-feeding is not recommended. Thiazides are excreted in human breast milk; benefits to the mother should be weighed against possible risk to the newborn if used in a nursing woman.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F225112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Micardis HCT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-12.5 mg (30): $160.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-12.5 mg (30): $160.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-25 mg (30): $160.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F225100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F225113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kinzalcomb (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Micardis HCT (BR);",
"     </li>",
"     <li>",
"      Micardis Plus (AR, AT, AU, BE, BG, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IT, KP, MY, NI, NL, NO, PA, PE, PH, PT, PY, RU, SE, SG, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Pritorplus (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, NL, NO, PH, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Telisid-H (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Telmisartan: Telmisartan is an angiotensin receptor antagonist. Angiotensin II acts as a vasoconstrictor. In addition to causing direct vasoconstriction, angiotensin II also stimulates the release of aldosterone. Once aldosterone is released, sodium as well as water are reabsorbed. The end result is an elevation in blood pressure. Telmisartan binds to the AT1 angiotensin II receptor. This binding prevents angiotensin II from binding to the receptor thereby blocking the vasoconstriction and the aldosterone secreting effects of angiotensin II.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydrochlorothiazide: Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K, Kjekshus J, et al, \"Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, \"Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, \"Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, \"Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, \"Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,\"",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15687/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9509 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-581423BC0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15687=[""].join("\n");
var outline_f15_20_15687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709067\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225117\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225118\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225136\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225121\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225122\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225123\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225124\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225102\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950985\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225087\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9614176\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225104\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225134\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225107\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225091\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225131\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225095\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225116\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225097\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225110\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225126\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225111\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225112\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225109\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225100\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225113\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225090\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225106\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/59/29621?source=related_link\">",
"      Telmisartan and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_20_15688="Promethazine: Drug information";
var content_f15_20_15688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Promethazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2806?source=see_link\">",
"    see \"Promethazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"    see \"Promethazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F214081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Phenadoz&reg;;",
"     </li>",
"     <li>",
"      Phenergan;",
"     </li>",
"     <li>",
"      Promethegan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F214082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bioniche Promethazine;",
"     </li>",
"     <li>",
"      Histantil;",
"     </li>",
"     <li>",
"      Phenergan;",
"     </li>",
"     <li>",
"      PMS-Promethazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F214126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Phenothiazine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F214085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic conditions",
"     </b>",
"     (including allergic reactions to blood or plasma):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, rectal: 25 mg at bedtime",
"     <b>",
"      or",
"     </b>",
"     12.5 mg before meals and at bedtime (range: 6.25-12.5 mg 3 times/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 25 mg, may repeat in 2 hours when necessary; switch to oral route as soon as feasible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"     Oral, I.M., I.V., rectal: 12.5-25 mg every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Motion sickness:",
"     </b>",
"     Oral, rectal: 25 mg 30-60 minutes before departure, then every 12 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Obstetrics (labor) analgesia adjunct:",
"     </b>",
"     I.M., I.V.: Early labor: 50 mg; Established labor: 25-75 mg in combination with analgesic at reduced dosage; may repeat every 4 hours for up to 2 additional doses (maximum: 100 mg/day while in labor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pre-/postoperative analgesia/hypnotic adjunct:",
"     </b>",
"     I.M., I.V.: 25-50 mg in combination with analgesic or hypnotic (at reduced dosage)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation:",
"     </b>",
"     Oral, I.M., I.V., rectal: 12.5-50 mg/dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F214105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"      see \"Promethazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic conditions:",
"     </b>",
"     Children &ge;2 years: Oral, rectal: 0.1 mg/kg/dose (maximum: 12.5 mg) every 6 hours during the day and 0.5 mg/kg/dose (maximum: 25 mg) at bedtime as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"     Children &ge;2 years: Oral, I.M., I.V., rectal: 0.25-1 mg/kg 4-6 times/day as needed (maximum: 25 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Motion sickness:",
"     </b>",
"     Children &ge;2 years: Oral, rectal: 0.5 mg/kg/dose 30 minutes to 1 hour before departure, then every 12 hours as needed (maximum dose: 25 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative analgesia/hypnotic adjunct:",
"     </b>",
"     Children &ge;2 years: I.M., I.V.: 1.1 mg/kg in combination with an analgesic or hypnotic (at reduced dosage) and with an atropine-like agent (at appropriate dosage).",
"     <b>",
"      Note:",
"     </b>",
"     Promethazine dosage should not exceed half of suggested adult dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation:",
"     </b>",
"     Children &ge;2 years: Oral, I.M., I.V., rectal: 12.5-25 mg at bedtime or preoperatively (maximum: 25 mg/dose)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F214086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 25 mg/mL (1 mL); 50 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenergan: 25 mg/mL (1 mL); 50 mg/mL (1 mL) [contains edetate disodium, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as hydrochloride: 12.5 mg (12s); 25 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenadoz&reg;: 12.5 mg (12s); 25 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Promethegan&trade;: 12.5 mg (12s); 25 mg (12s); 50 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 6.25 mg/5 mL (118 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 12.5 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F214056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Formulations available for oral, rectal, I.M./I.V.; not for SubQ administration. Administer I.M. into deep muscle (preferred route of administration). I.V. administration is",
"     <b>",
"      not",
"     </b>",
"     the preferred route; severe tissue damage may occur. Solution for injection should be administered in a maximum concentration of 25 mg/mL (more dilute solutions are recommended). Administer via running I.V. line at port farthest from patient's vein, or through a large bore vein (not hand or wrist). Consider administering over 10-15 minutes (maximum: 25 mg/minute). Discontinue immediately if burning or pain occurs with administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F214133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amsacrine, aztreonam, bivalirudin, ciprofloxacin, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, etoposide phosphate, fenoldopam, filgrastim, fluconazole, fludarabine, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, melphalan, ondansetron, oxaliplatin, palonosetron, pemetrexed, remifentanil, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, cefotetan, doxorubicin liposome, foscarnet, furosemide, methotrexate, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cefazolin, heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, atropine with meperidine, butorphanol, chlorpromazine, cimetidine, dihydroergotamine, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, midazolam, pentazocine, prochlorperazine edisylate, ranitidine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefotetan, ceftriaxone, dexamethasone sodium phosphate, dimenhydrinate, heparin, iodipamide meglumine 52%, iothalamate meglumine 60%, iothalamate sodium 80%, ketorolac, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydromorphone, morphine, nalbuphine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F214055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of various allergic conditions; antiemetic; motion sickness; sedative; adjunct to postoperative analgesia and anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14456627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nausea and vomiting of pregnancy (NVP)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F214135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Promethazine may be confused with chlorproMAZINE, predniSONE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Phenergan&reg; may be confused with PHENobarbital, Phrenilin&reg;, Theragran",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       To prevent or minimize tissue damage during I.V. administration, the Institute for Safe Medication Practices (ISMP) has the following recommendations:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Limit concentration available to the 25 mg/mL product",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Consider limiting initial doses to 6.25-12.5 mg",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Further dilute the 25 mg/mL strength into 10-20 mL NS",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Administer through a large bore vein (not hand or wrist)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Administer via running I.V. line at port farthest from patient's vein",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Consider administering over 10-15 minutes",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Instruct patients to report immediately signs of pain or burning",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sominex: Brand name for promethazine in Great Britain, but also is a brand name for diphenhydrAMINE in the U.S.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F214124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hyper-/hypotension, nonspecific QT changes, orthostatic hypotension, tachycardia,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation akathisia, catatonic states, confusion, delirium, disorientation, dizziness, drowsiness, dystonias, euphoria, excitation, extrapyramidal symptoms, faintness, fatigue, hallucinations, hysteria, insomnia, lassitude, pseudoparkinsonism, tardive dyskinesia, nervousness, neuroleptic malignant syndrome, nightmares, sedation, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, dermatitis, photosensitivity, skin pigmentation (slate gray), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast engorgement, gynecomastia, hyperglycemia, lactation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculatory disorder, impotence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, leukopenia, thrombocytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Abscess, distal vessel spasm, gangrene, injection site reactions (burning, edema, erythema, pain), palsies, paralysis, phlebitis, sensory loss, thrombophlebitis, tissue necrosis, venous thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Incoordination, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, corneal and lenticular changes, diplopia, epithelial keratopathy, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, asthma, nasal congestion, respiratory depression",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F214059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to promethazine or any component of the formulation (cross-reactivity between phenothiazines may occur); coma; treatment of lower respiratory tract symptoms, including asthma; children &lt;2 years of age; intra-arterial or subcutaneous administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F214041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Phenothiazines may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); therefore, they should be used with caution in patients with decreased gastrointestinal motility, gastrointestinal obstructions (partial or complete), urinary retention, urinary obstructions (partial or complete), BPH, xerostomia, or visual problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitivity; avoid prolonged sun exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious tissue injury:",
"     <b>",
"      [U.S. Boxed Warning]: Promethazine injection can cause severe tissue injury (including gangrene) regardless of the route of administration. Tissue irritation and damage may result from perivascular extravasation, unintentional intra-arterial administration, and intraneuronal or perineuronal infiltration. In addition to gangrene, adverse events reported include tissue necrosis, abscesses, burning, pain, erythema, edema, paralysis, severe spasm of distal vessels, phlebitis, thrombophlebitis, venous thrombosis, sensory loss, paralysis, and palsies. Surgical intervention including fasciotomy, skin graft, and/or amputation have been necessary in some cases. The preferred route of administration is by deep intramuscular (I.M.) injection.  Subcutaneous administration is contraindicated. Discontinue intravenous injection immediately with onset of burning and/or pain and evaluate for arterial injection or perivascular extravasation. Although there is no proven successful management of unintentional intra-arterial injection or perivascular extravasation, sympathetic block and heparinization have been used in the acute management of unintentional intra-arterial injection based on results from animal studies.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Use with caution in patients with bone marrow suppression; leukopenia and agranulocytosis have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment. Cholestatic jaundice has been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; may have increased risk of tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Avoid use in patients with severe respiratory disease (asthma, COPD, sleep apnea); may lead to potentially fatal respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of this potent anticholinergic agent due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Respiratory fatalities have been reported in children &lt;2 years of age. Use contraindicated in children &lt;2 years. In children &ge;2 years, use the lowest possible dose; other drugs with respiratory depressant effects should be avoided.",
"     </b>",
"     Avoid use in children who may have Reyes&rsquo; syndrome or hepatic disease as adverse reactions caused by promethazine may be confused with signs of primary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: Injection may contain sodium metabisulfite; may cause allergic reaction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Nasal): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Epinephrine (Racemic): Promethazine may diminish the vasoconstricting effect of Epinephrine (Racemic).  Management: Monitor for diminished vasoconstrictive effects of racemic epinephrine (e.g., diminished efficacy when used for gingival retraction).  This interaction is likely of less concern in patients receiving epinephrine for other purposes (e.g., bronchodilation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Systemic, Oral Inhalation): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation).  Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Promethazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Promethazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F214076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Promethazine crosses the placenta. Maternal promethazine use has generally not resulted in an increased risk of birth defects. Platelet aggregation may be inhibited in newborns following maternal use of promethazine within 2 weeks of delivery. Promethazine is used for the treatment of nausea and vomiting of pregnancy (refer to current guidelines). Promethazine is also indicated for use during labor for obstetric sedation and may be used alone or as an adjunct to narcotic analgesics.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F214091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14456628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if promethazine is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F214063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase dietary intake of riboflavin.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F214061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Phenergan Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (1 mL): $2.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (1 mL): $3.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Promethazine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (1 mL): $1.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (1 mL): $2.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Phenadoz Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (12): $53.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Promethazine HCl Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (12): $46.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (12): $52.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Promethegan Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (12): $70.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (12): $70.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (12): $231.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Promethazine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25 mg/5 mL (473 mL): $22.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Promethazine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $49.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $50.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $77.62",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F214051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms, mental status; signs and symptoms of tissue injury (burning or pain at injection site, phlebitis, edema) with I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Allerfen (IT);",
"     </li>",
"     <li>",
"      Allersoothe (NZ);",
"     </li>",
"     <li>",
"      Antiallersin (BG);",
"     </li>",
"     <li>",
"      Atosil (DE);",
"     </li>",
"     <li>",
"      Diphergan (PL);",
"     </li>",
"     <li>",
"      Duplamin (IT);",
"     </li>",
"     <li>",
"      Fargan (IT);",
"     </li>",
"     <li>",
"      Farganesse (IT);",
"     </li>",
"     <li>",
"      Fenazil (IT);",
"     </li>",
"     <li>",
"      Fenazine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fenergan (AR, ES, PE, PT, PY, UY, VE);",
"     </li>",
"     <li>",
"      Frinova (ES);",
"     </li>",
"     <li>",
"      Hibechin (JP);",
"     </li>",
"     <li>",
"      Hiberna (JP);",
"     </li>",
"     <li>",
"      Histazin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lergigan (SE);",
"     </li>",
"     <li>",
"      Meta (TH);",
"     </li>",
"     <li>",
"      Phenergan (AE, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CY, DK, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, IE, IN, IQ, IR, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PK, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Phenerzin (PH);",
"     </li>",
"     <li>",
"      Pipolphen (HN, HU);",
"     </li>",
"     <li>",
"      Profergan (BR);",
"     </li>",
"     <li>",
"      Prome (ID);",
"     </li>",
"     <li>",
"      Promet (PH);",
"     </li>",
"     <li>",
"      Prometazina (IT);",
"     </li>",
"     <li>",
"      Prometazina Cloridrato (IT);",
"     </li>",
"     <li>",
"      Proneurin (DE);",
"     </li>",
"     <li>",
"      Prothazin (CZ);",
"     </li>",
"     <li>",
"      Prothiazine (IL);",
"     </li>",
"     <li>",
"      Pyrethia (JP);",
"     </li>",
"     <li>",
"      Sandoz Fenezal (AU);",
"     </li>",
"     <li>",
"      Sayomol (ES);",
"     </li>",
"     <li>",
"      Sylomet (PH);",
"     </li>",
"     <li>",
"      Xepagan (MY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F214040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenothiazine derivative; blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; competes with histamine for the H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor; muscarinic-blocking effect may be responsible for antiemetic activity; reduces stimuli to the brainstem reticular system",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F214058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral, I.M.: ~20 minutes; I.V.: ~5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Usually 4-6 hours (up to 12 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete; large first pass effect limits systemic bioavailability (Sharma, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Syrup: 98 L/kg (range: 17-277 L/kg) (Strenkoski-Nox,  2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; hydroxylation via CYP2D6 and N-demethylation via CYP2B6; significant first-pass effect (Sharma, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~25% (Sharma, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.M.: ~10 hours; I.V.: 9-16 hours; Suppositories, syrup: 16-19 hours (range: 4-34 hours) (Strenkoski-Nox, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to maximum serum concentration: Suppositories: 6.7-8.6 hours; Syrup: 4.4 hours (Strenkoski-Nox,  2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetrics and Gynecology, \"ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: Nausea and Vomiting of Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 103(4):803-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/15051578/pubmed\" id=\"15051578\" target=\"_blank\">",
"        15051578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blanc VF, Ruest P, Milot J, et al, &ldquo;Antiemetic Prophylaxis With Promethazine or Droperidol in Paediatric Outpatient Strabismus Surgery,&rdquo;",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 1991, 38(1):54-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/1989740/pubmed\" id=\"1989740\" target=\"_blank\">",
"        1989740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grunberg SM and Hesketh PJ, &ldquo;Control of Chemotherapy-Induced Emesis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(24):1790-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/8232489/pubmed\" id=\"8232489\" target=\"_blank\">",
"        8232489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice, &ldquo;Action Needed to Prevent Serious Tissue Injury With I.V. Promethazine.&rdquo; Available at file://www.ismp.org/Newsletters/acutecare/articles/20060810.asp",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee JL and Alexander MR, &ldquo;Phenothiazine Analgesia - Fact or Fantasy?&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1979, 36(5):633-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/36754/pubmed\" id=\"36754\" target=\"_blank\">",
"        36754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Melanson SE, Lee-Lewandrowski E, Griggs DA, et al, &ldquo;Reduced Interference by Phenothiazines in Amphetamine Drug of Abuse Immunoassays,&rdquo;",
"      <i>",
"       Arch Pathol Lab Med",
"      </i>",
"      , 2006, 130(12):1834-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/17149959/pubmed\" id=\"17149959\" target=\"_blank\">",
"        17149959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parkman HP, Hasler WL, Fisher RS, &ldquo;American Gastroenterological Association Medical Position Statement: Diagnosis and Treatment of Gastroparesis,&rdquo; Gastroenterology, 2004, 127(5):1589-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/15521025/pubmed\" id=\"15521025\" target=\"_blank\">",
"        15521025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharma A and Hamelin BA, \"Classic Histamine H1 Receptor Antagonists: A Critical Review of Their Metabolic and Pharmacokinetic Fate from a Bird's Eye View,\"",
"      <i>",
"       Curr Drug Metab",
"      </i>",
"      , 2003, 4(2):105-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/12678691/pubmed\" id=\"12678691\" target=\"_blank\">",
"        12678691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke PR, Weaver J, and Chowdhury BA, &ldquo;Boxed Warning Added to Promethazine Labeling for Pediatric Use,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(25):2653.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/15972879/pubmed\" id=\"15972879\" target=\"_blank\">",
"        15972879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strenkoski-Nix LC, Ermer J, DeCleene S, et al, &ldquo;Pharmacokinetics of Promethazine Hydrochloride After Administration of Rectal Suppositories and Oral Syrup to Healthy Subjects,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2000, 57(16):1499-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/10965395/pubmed\" id=\"10965395\" target=\"_blank\">",
"        10965395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tavorath R and Hesketh PJ, &ldquo;Drug Treatment of Chemotherapy-Induced Delayed Emesis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 52(5):639-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/9118814/pubmed\" id=\"9118814\" target=\"_blank\">",
"        9118814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor G, Houston JB, Shaffer J, et al, &ldquo;Pharmacokinetics of Promethazine and Its Sulphoxide Metabolite After Intravenous and Oral Administration To Man,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1983, 15(3):287-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/6849764/pubmed\" id=\"6849764\" target=\"_blank\">",
"        6849764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tortorice PV and O'Connell MB, &ldquo;Management of Chemotherapy-Induced Nausea and Vomiting,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1990, 10(2):129-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/20/15688/abstract-text/2190193/pubmed\" id=\"2190193\" target=\"_blank\">",
"        2190193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9820 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15688=[""].join("\n");
var outline_f15_20_15688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709344\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214081\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214082\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214126\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214085\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214105\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214086\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214053\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214037\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214056\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214133\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214055\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456627\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214135\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214124\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214059\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214041\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214122\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214046\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214076\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214049\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214062\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214091\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456628\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214063\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214061\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214051\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038783\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214040\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214058\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2806?source=related_link\">",
"      Promethazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=related_link\">",
"      Promethazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_20_15689="Asperger disorder: Clinical features and diagnosis in children and adolescents";
var content_f15_20_15689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Asperger disorder: Clinical features and diagnosis in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15689/contributors\">",
"     L. Erik von Hahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15689/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15689/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15689/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/20/15689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/20/15689/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/20/15689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Psychiatric Association recognized Asperger disorder as a specific entity by publishing diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) in 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/1\">",
"     1",
"    </a>",
"    ]. A modest but growing literature on Asperger disorder has emerged since then, though questions remain about Asperger disorder as a distinct clinical entity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of Asperger disorder will be reviewed here. The management and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=see_link\">",
"     \"Asperger disorder: Management and prognosis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians consider Asperger disorder (also called Asperger syndrome) (",
"    <a class=\"graphic graphic_table graphicRef60599 \" href=\"UTD.htm?12/57/13212\">",
"     table 1",
"    </a>",
"    ) to be an \"autism spectrum disorder\" (ASD) or \"pervasive developmental disorder\" (PDD). These terms refer to a heterogeneous group of neurodevelopmental disorders that have diverse etiologies but are characterized by constellations of symptoms involving deficits in reciprocal social interaction, communication, and behavior (specifically stereotyped interests and activities) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The other autism spectrum disorders are autistic disorder (",
"    <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"     table 2",
"    </a>",
"    ), Rett disorder, childhood disintegrative disorder, and pervasive developmental disorder-not otherwise specified (PDD-NOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H2#H2\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to draw firm conclusions regarding the prevalence of Asperger disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/8\">",
"     8",
"    </a>",
"    ]. There are few studies on Asperger disorder as a distinct clinical entity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Prevalence is usually determined by subgrouping within the autism spectrum and varies widely depending upon the diagnostic criteria used to identify cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/12-16\">",
"     12-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In systematic reviews, the prevalence of Asperger disorder is estimated to be 6 cases per 10,000 based upon an autistic disorder-to-Asperger disorder ratio of 3 or 4 to 1, though there are strong limitations of available data on Asperger disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asperger disorder is more commonly diagnosed in males. The male:female ratio is approximately to 5:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/11-16\">",
"     11-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes for Asperger disorder have not been studied systematically. However, most clinicians accept the hypothesis that Asperger disorder represents one end of the autism spectrum. If this is the case, the causes of Asperger disorder would be expected to be the same as the causes of autism. The etiology of autism has yet to be determined. However, genetic and neurobiologic factors appear to play a prominent role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H12#H12\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case reports and family studies suggest that Asperger disorder runs in families [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/18\">",
"     18",
"    </a>",
"    ]. Forms of Asperger disorder have been mapped to chromosome 3q (ASPG1), chromosome 17p (ASPG2), and chromosome 1q21-q22 (ASPG3) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise neuroanatomical or neurophysiological differences that underlie Asperger disorder are not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. Observational studies describe different patterns of grey matter volume in children with Asperger disorder than in children with high-functioning autism and control children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of Asperger disorder is atypical social development (eg, lack of social awareness, inability to socialize, lack of interest in socializing) accompanied by extreme behavioral rigidity. Atypical social development can be difficult to identify before approximately four years of age, although other symptoms may be present earlier. In a survey of parents of 156 children with Asperger disorder, the average age at diagnosis was 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/23\">",
"     23",
"    </a>",
"    ]. However, parental concerns were present at an average age of 30 months. The average age of diagnosis for Asperger disorder may decline as the awareness of the autism spectrum grows.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Early features",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the preschool years, children with Asperger disorder may be asymptomatic, may have symptoms that are below the threshold of clinical concern, or may have symptoms related to an associated or comorbid condition (behavior disorder, attention deficit hyperactivity disorder, or anxiety). &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Associated conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Before four years of age, children with Asperger disorder may have delayed use of gestures, joint attention, or pointing and referring to an object of interest (classic features of an autism spectrum disorder). However, because children with Asperger disorder usually have normal language development and ability to communicate their wants and needs, these atypical features may not appear salient to caregivers. Depending upon the severity of repetitive behaviors, a diagnosis of PDD-NOS is sometimes made in the child with Asperger disorder during the preschool years.",
"   </p>",
"   <p>",
"    After four years of age, when social expectations increase, the atypical social development of children with Asperger disorder becomes more noticeable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/25\">",
"     25",
"    </a>",
"    ]. Parents and teachers may begin to question social development, identifying a lack of social awareness or social ability, the main feature of Asperger disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Social skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal social development and interaction encompass the following types of skills:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Communication &mdash; Communicating thoughts, intentions, and emotions verbally and nonverbally.",
"     </li>",
"     <li>",
"      Social conventions &mdash; Understanding and using social conventions (eg, greetings, waiting turns, following rules, etc.).",
"     </li>",
"     <li>",
"      Social reasoning (\"theory of mind\") &mdash; Being able to infer the thoughts, intentions, or emotions of others based upon verbal and nonverbal communication (eg, facial expression, gestures, body language).",
"     </li>",
"     <li>",
"      On-line modification of social behaviors&mdash; Modifying one's behavior during social interactions by considering information obtained through knowledge of the above three components.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The atypical social development of individuals with Asperger disorder is usually obvious by the time the child reaches school age if it is not apparent earlier. Day care and preschool staff may notice the child's developmental differences before the parents do, having the benefit of seeing the child interact with same-age peers. The child may solicit the attention of other children or adults inappropriately (eg, by pushing, by approaching the person while failing to respect personal boundaries, or by immediately initiating a discussion about their preferred topic of interest without checking to see if the peer or adult is listening or even interested). Alternatively, the child may play in the midst of other children without any awareness of what the other children are doing and may not show any ability or effort to join in their play.",
"   </p>",
"   <p>",
"    During interactions with the clinician, the child may avoid eye gaze, may gaze too intently, or may gaze at the clinician's mouth or other parts of the face or body instead of directing",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    gaze at the eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/26\">",
"     26",
"    </a>",
"    ]. The child may have an invariant expression and may not use gestures as naturally or spontaneously as other individuals. Sometimes, children with Asperger disorder make facial expressions or gestures that are exaggerated or \"scripted,\" which also makes them appear awkward.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Language skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with Asperger disorder perform normally on formal tests of language function (ie, tests that measure vocabulary, syntax, and semantics). However, they do not understand or use language normally [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/8,27\">",
"     8,27",
"    </a>",
"    ]. Atypical prosodic (rate, rhythm, tone, and volume) and pragmatic (social and nonverbal) features of language in individuals with Asperger disorder are more apparent after four years of age.",
"   </p>",
"   <p>",
"    Prosodic differences include speaking in a pedantic manner (eg, sounding like a professor), using an invariant tone of voice, or speaking in an overly expressive or theatrical manner that is inappropriate to the context and is usually scripted. The rate of speech may be too slow or too fast, and the pitch too loud.",
"   </p>",
"   <p>",
"    Children with normal pragmatic language skills can speak in logically sequenced sentences (narrative language) and participate in conversations by providing contingent (on-topic) responses (even if only for short exchanges) by the age of five years. In contrast, in children with Asperger disorder, narrative language may be disorganized or tangential, and conversations may be focused on a narrow topic of interest.",
"   </p>",
"   <p>",
"    Children with Asperger disorder understand language literally. They have difficulty understanding how the meaning of language changes with context. They may not understand, for example, that a change in tone of voice can change the meaning of a word or sentence, or that the same word can have more than one meaning, skills that are present in typically developing children by six to seven years of age. Lacking these skills, children with Asperger disorder may have difficulty understanding metaphors, humor, sarcasm, teasing, jokes, and deception [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although children with Asperger disorder can be taught to notice ambiguous features of language such as those listed above, they generally never fully master all of these subtleties of language. In addition, once they have learned to notice pragmatic functions such as sarcasm or humor, they may use them inappropriately (eg, by inappropriately making sarcastic remarks to older peers or adults or by inappropriately attempting to make a joke), or they may misinterpret the comments of a peer as being sarcastic when they were not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Behavioral features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Asperger disorder may present with behavioral disturbances before their atypical social or language skills are apparent. Behavior disturbances continue throughout life.",
"   </p>",
"   <p>",
"    Repetitive and perseverative interests are defining features of Asperger disorder and are especially obvious when they persist into school age. Although repetitive interests are common in young children, children with Asperger disorder are different because their perseverative interests are more specific, unusual, and intense than is the case for their typically developing peers. Interest in mechanical topics, such as trains and cars, or topics from the natural sciences is common. The interest may be very narrow (eg, limited to ceiling fans or vacuum cleaners). They have marked difficulty shifting their attention away from their preferred topic, even when provided with multiple cues, prompts, or requests.",
"   </p>",
"   <p>",
"    Inflexibility (cognitive rigidity) is another important behavioral feature in individuals with Asperger disorder. This feature may be apparent in their choice of conversational topics, but may also be noticeable by their intolerance of changes to their routine or",
"    <span class=\"nowrap\">",
"     changes/violations",
"    </span>",
"    of rules of conduct. They are quick to point out differences from what they perceive to be \"normal\" or \"expected.\" Changes in routines or rules can provoke temper tantrums",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety.",
"   </p>",
"   <p>",
"    Despite their adherence to routines, children with Asperger disorder can be disorganized and have marked difficulty completing chores or daily tasks. Sometimes this is related to their overfixation on a preferred topic of interest, which diverts their attention away from the more routine tasks of the day. At other times, failure to complete daily tasks may be related to executive dysfunctions, such as remembering, planning, and completing tasks (both routine and novel), and their inability to solve novel problems in real-time situations.",
"   </p>",
"   <p>",
"    Children with Asperger disorder may be unusually sensitive to noises, touch, odors, tastes, or visual stimuli. These sensory sensitivities heighten their overall level of arousal and can contribute to inattention, anxiety,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anger management problems.",
"   </p>",
"   <p>",
"    Other behavior disturbances in children with Asperger disorder include anxiety, disruptive behavior disorders (eg, aggression, self-injury), and executive dysfunction, which also occurs in attention deficit hyperactivity disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Associated conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clumsiness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clumsiness is commonly present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/10,30\">",
"     10,30",
"    </a>",
"    ], though it is not a defining feature in the DSM-IV criteria (",
"    <a class=\"graphic graphic_table graphicRef60599 \" href=\"UTD.htm?12/57/13212\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     School performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Asperger disorder typically perform well with the rote learning that is the focus of schooling during the primary school years. However, school performance often declines in third or fourth grade, when reading comprehension and written expression become more important, a consequence of limited pragmatic language skills and social awareness. Children with Asperger disorder perform especially poorly in topics not related to their preferred interests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when group learning or classroom discussion is required. They can easily become overwhelmed when asked to manage their own schedule, to keep track of their own homework assignments, complete complex assignments such as book reports or essays, etc.",
"   </p>",
"   <p>",
"    As children with Asperger disorder enter high school, they may have difficulty understanding concepts that are taught in a typical high school curriculum (eg, understanding character development or character motivation in works of fiction and historical and social concepts, such as \"peace,\" \"justice,\" \"liberty,\" etc.).",
"   </p>",
"   <p>",
"    Special education supports often are needed by third or fourth grade, though not all school teams recognize the need for such supports because students with Asperger disorder can perform successfully on standardized measures of educational achievement. Lack of academic supports can lead to frustration and behavior disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=see_link&amp;anchor=H9#H9\">",
"     \"Asperger disorder: Management and prognosis in children and adolescents\", section on 'Academic supports for reading and writing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric conditions that are associated with Asperger disorder include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/24,31-36\">",
"     24,31-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety disorder",
"     </li>",
"     <li>",
"      Oppositional defiant disorder and other disruptive behavior disorders",
"     </li>",
"     <li>",
"      Attention deficit hyperactivity disorder (ADHD)",
"     </li>",
"     <li>",
"      Depression and other mood disorders",
"     </li>",
"     <li>",
"      Nonverbal learning disability (a condition not recognized by the DSM)",
"     </li>",
"     <li>",
"      Tic disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of comorbid conditions is uncertain, given limited research on Asperger disorder as a distinct clinical entity and problems with case definition. However, several case series suggest that the majority of children and adolescents with Asperger disorder have a comorbid psychiatric diagnosis or symptoms of a comorbid psychiatric diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/31-33,35\">",
"     31-33,35",
"    </a>",
"    ]. In one study of 50 9- to 16-year-old subjects with either Asperger disorder or high-functioning autism, the rate of comorbid psychiatric conditions was estimated to be 74 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/37\">",
"     37",
"    </a>",
"    ]. Among the comorbid diagnoses, ADHD appears to be more common in preadolescents, and depression in adolescents and adults.",
"   </p>",
"   <p>",
"    Symptoms of comorbid conditions (eg, depression, anxiety) may be exacerbated by negative social experiences and increased awareness of differences and social difficulties (eg, isolation, marginalization, and bullying) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/3,38,39\">",
"     3,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asperger disorder affects multiple areas of function. Clinical assessment of children with suspected Asperger disorder is most effectively conducted by a multidisciplinary team [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2,40\">",
"     2,40",
"    </a>",
"    ]. The primary objective of the diagnostic assessment is to establish a comprehensive profile of the child's strengths, weaknesses, and challenges to formulate an individualized management plan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=see_link\">",
"     \"Asperger disorder: Management and prognosis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Role of the primary care provider",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asperger disorder may not be suspected by the primary care provider unless the parents have specific concerns. Children with Asperger disorder often are able to manage the social demands of a routine pediatric office visit successfully and would not necessarily appear to be \"odd\" or to lack social awareness, especially if they are intelligent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have been given some instruction about how to behave in the clinician&rsquo;s office.",
"   </p>",
"   <p>",
"    Questions that may be helpful in eliciting concerns related to the symptoms of Asperger disorder include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Did you have concerns regarding your child's language development before the age of three?\"",
"     </li>",
"     <li>",
"      \"When your child developed speech, did it appear to be formal in nature or precociously verbose?\"",
"     </li>",
"     <li>",
"      \"Does your child have any unusual interests or preoccupations with certain topics? If so, to what extent do they interfere with the child's ability to engage in social exchanges?\"",
"     </li>",
"     <li>",
"      \"Do you have any concerns regarding your child's socialization and play skills? What does",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      like to play with? Whom does",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      like to play with? What do they do together?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If parents express concerns suggestive of Asperger disorder, the clinician can engage the child in an open-ended conversation and observe the child more closely for evidence of atypical social and language behaviors. The pediatric health care provider can ask the child about friendships, what",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    likes to do during play dates or play time, etc. Both the content of the child&rsquo;s responses and the style of responding can reveal atypical language and social behaviors.",
"   </p>",
"   <p>",
"    When Asperger disorder is suspected, the primary care provider's main roles are to help the family access the resources needed to establish the diagnosis and to advocate for optimal service delivery at school and in the community. Although the primary care provider may be able to diagnose Asperger disorder, referral to a specialist is warranted to confirm the diagnosis and to assure that all of the child's needs are met. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=see_link\">",
"     \"Asperger disorder: Management and prognosis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the clinician suspects Asperger disorder (or another autism spectrum disorder), the child should be referred for evaluation by a developmental-behavioral pediatrician, a child psychiatrist, a child neurologist, or a neuropsychologist with expertise in autism spectrum disorders for a multidisciplinary evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Multidisciplinary evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Such referrals often involve a long waiting period. The primary care provider can facilitate the process by helping the parents to gather information in advance of consultation with the specialist. As an example, the parents could be provided with rating scales for autism, Asperger disorder, child psychiatric disorders,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral disorders. Several scales have been designed specifically for Asperger disorder (",
"    <a class=\"graphic graphic_table graphicRef59075 \" href=\"UTD.htm?29/36/30285\">",
"     table 3",
"    </a>",
"    ). However, their psychometric properties are not always reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/6,42\">",
"     6,42",
"    </a>",
"    ]. A general behavioral screening tool is worthwhile to capture some of the behavioral or atypical features (eg, the Behavior Assessment System for Children (BASC) or the Child Behavior Checklist (CBCL)) and facilitates the assessment of comorbid conditions and other conditions in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnostic tools'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14361?source=see_link\">",
"     \"Screening tools for autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link\">",
"     \"Developmental and behavioral screening tests in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary care provider also can request or recommend psychoeducational and",
"    <span class=\"nowrap\">",
"     speech/language",
"    </span>",
"    testing by the child's school district. The main purposes of school testing are to assess the child's cognitive and educational functioning and language skills. It is useful to ask the school team to look at pragmatic functions specifically, and to assess social skills and behavioral regulation (capacity for self-organization, keeping track of homework and of personal belongings). Additional areas may warrant evaluation if the child has motor coordination problems or there are other concerns (eg, behavioral or emotional problems).",
"   </p>",
"   <p>",
"    Finally, the primary care provider can refer parents and patients to support organizations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Web sites. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Multidisciplinary evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asperger disorder affects multiple areas of function, and clinical assessment of children with suspected Asperger disorder is most effectively conducted by a multidisciplinary team [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. The primary objective of the assessment is to establish a comprehensive, detailed profile of the child's strengths, weaknesses, and challenges.",
"   </p>",
"   <p>",
"    The evaluation should include a history of the child's early development, current symptoms, speech and language assessment, and neuropsychologic testing to differentiate Asperger disorder from other conditions in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef80236 \" href=\"UTD.htm?6/3/6205\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Associated conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The developmental and health history may help to distinguish Asperger disorder from other autism spectrum disorders and other biological and psychiatric disorders. It should include observations of the child during more and less structured periods. Specific areas for observation and inquiry include [",
"      <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2\">",
"       2",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Development of peer relationships and friendships",
"     </li>",
"     <li>",
"      Patterns of special interest and leisure time",
"     </li>",
"     <li>",
"      Presence of obsessions or compulsions",
"     </li>",
"     <li>",
"      Ritualized behaviors",
"     </li>",
"     <li>",
"      Depression and panic attacks or other symptoms of anxiety",
"     </li>",
"     <li>",
"      Capacity for self-awareness and perspective-taking",
"     </li>",
"     <li>",
"      Level of insight into social and behavioral problems",
"     </li>",
"     <li>",
"      Typical reactions in novel situations",
"     </li>",
"     <li>",
"      Social and affective presentation",
"     </li>",
"     <li>",
"      Quality of attachment to family members",
"     </li>",
"     <li>",
"      Ability to infer another person's feelings, intentions, beliefs",
"     </li>",
"     <li>",
"      Ability to understand ambiguous nonliteral communication (eg, the ability to understand an expression like \"it's raining cats and dogs\"; metaphors; sarcasm; etc.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physical examination of children with Asperger disorder usually is normal. Important aspects of the examination include assessment of dysmorphic features, neurologic examination, and evaluation of the skin for pigmentary changes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link&amp;anchor=H6#H6\">",
"       \"Diagnosis of autism spectrum disorders\", section on 'Examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The speech and language assessment provides a profile of language skills and may differentiate Asperger disorder from autistic disorder and specific language disorder. Important aspects of the assessment include an assessment of pragmatic language functions, such as nonverbal communication, nonliteral language (eg, metaphor, humor), content of conversations, and capacity to respond to conversational demands with contingent responses (staying on topic). Prosodic features such as rate, rhythm, and volume of speech are often abnormal [",
"      <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2\">",
"       2",
"      </a>",
"      ]. These language features are not always captured in a",
"      <span class=\"nowrap\">",
"       speech/language",
"      </span>",
"      assessment that focuses on formal language functions only (vocabulary, grammar and syntax). The tester has to understand pragmatic language functions and probe for them specifically; pragmatic language tests are subject to significant observer interpretation; and individuals with Asperger disorder may perform successfully in the 1:1 testing situation, even though they do not show normal pragmatic language skills when asked to participate in real-time situations, such as classroom discussions or peer interactions.",
"     </li>",
"     <li>",
"      Neuropsychological assessment is performed to establish the overall level of intellectual functioning, profiles of psychomotor functioning, verbal and nonverbal cognitive strengths and weaknesses, style of learning, and independent living skills [",
"      <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for making a diagnosis of Asperger disorder combines clinical judgment (ie, identification of the clinical features (",
"    <a class=\"graphic graphic_table graphicRef60599 \" href=\"UTD.htm?12/57/13212\">",
"     table 1",
"    </a>",
"    ) using history and clinical observations) and a formal diagnostic interview (ie, using a diagnostic tool for autism or Asperger disorder) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that the DSM-IV criteria (",
"    <a class=\"graphic graphic_table graphicRef60599 \" href=\"UTD.htm?12/57/13212\">",
"     table 1",
"    </a>",
"    ) be used to make the diagnosis of Asperger disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/43\">",
"     43",
"    </a>",
"    ]. Other sets of diagnostic criteria include the ICD-10 criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/44\">",
"     44",
"    </a>",
"    ], the Gillberg criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/10\">",
"     10",
"    </a>",
"    ], and the Szatmari criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/45\">",
"     45",
"    </a>",
"    ]. Each of these sets of criteria requires a certain number of items to be fulfilled, but none measures symptom severity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/15\">",
"     15",
"    </a>",
"    ]. The DSM-IV and ICD-10 criteria, which are most often used in research settings, are nearly identical, except that the DSM-IV requires the symptoms to cause clinically significant impairment in social, occupational, or other important areas of functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnostic tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rating scales and other semistructured interviews can facilitate the diagnosis of Asperger disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/8\">",
"     8",
"    </a>",
"    ]. However, these tools must be used in the context of clinical judgment; they should not be used in isolation to make a diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/6,8,27\">",
"     6,8,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Autism Diagnostic Interview Revised (ADI-R, a semistructured interview with a primary caregiver) and the Autism Diagnostic Observation Schedule (ADOS, a semistructured",
"    <span class=\"nowrap\">",
"     play/interactive",
"    </span>",
"    session) are used in the diagnosis of autism spectrum disorders. Using the ADOS or the ADI constitutes the best practice in the diagnosis of Asperger disorder. However, the diagnosis of Asperger disorder frequently is made without these tools. The ADI-R is primarily used in research settings. The ADOS requires 30 to 40 minutes to administer and requires specific training for clinical use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis of autism spectrum disorders\", section on 'Diagnostic tools'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rating scales for Asperger disorder are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef59075 \" href=\"UTD.htm?29/36/30285\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/6,27,42\">",
"     6,27,42",
"    </a>",
"    ]. Each of these scales has psychometric weaknesses; none should be used in isolation to make the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/27,42\">",
"     27,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of an autism spectrum disorder is confirmed, additional evaluation may be indicated to identify comorbid conditions that have important implications for treatment or genetic counseling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to definitively exclude some conditions from the differential diagnosis. Additional evaluation for children with autism spectrum disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnosis of autism spectrum disorders\", section on 'Additional evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of Asperger disorder includes other diagnoses within the autism spectrum and other disorders.",
"   </p>",
"   <p>",
"    Diagnostic overlap and comorbidity occurs in most mental health conditions; autism spectrum disorders are no exception [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/46\">",
"     46",
"    </a>",
"    ]. Not only are comorbid conditions present in individuals on the autism spectrum, but autistic symptoms (eg, weak social skills and others) are present in other mental health conditions (eg, obsessive-compulsive disorder, attention deficit hyperactivity disorder) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. This exposes the question of diagnostic reliability and validity in mental health conditions in general, and reflects the field's current inability to apply a single diagnostic explanation for symptoms in any given individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Within autism spectrum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Debate continues about how best to define Asperger disorder and how to distinguish it clinically from autistic disorder and PDD-NOS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2\">",
"     2",
"    </a>",
"    ]. Although absence of language impairment before age three, normal language skills, and normal intelligence often are used to distinguish between Asperger disorder (",
"    <a class=\"graphic graphic_table graphicRef60599 \" href=\"UTD.htm?12/57/13212\">",
"     table 1",
"    </a>",
"    ) and autistic disorder (",
"    <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"     table 2",
"    </a>",
"    ), the ability of these criteria to truly distinguish Asperger disorder, autistic disorder, and PDD-NOS is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]. There are varying degrees of clinical impairment within each of the three conditions, which also are not accounted for by the DSM IV criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"High-functioning autism\" (HFA) is a term used to describe autistic individuals with intelligence quotient (IQ) &gt;70 (ie, intelligence in the borderline range or above). This term may generate confusion about the child's needs because, in spite of their normal overall intelligence, children with HFA often function poorly at school and home (ie, they are not &ldquo;high functioning&rdquo; in the commonly understood sense of the word). There is some controversy regarding whether Asperger disorder is a form of HFA or a separate disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. There are no formal criteria for HFA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other psychiatric conditions share clinical features or occur as a comorbidity with Asperger disorder. These include (",
"    <a class=\"graphic graphic_table graphicRef80236 \" href=\"UTD.htm?6/3/6205\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/2,27,46-48\">",
"     2,27,46-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety disorder (including social phobia and selective mutism)",
"     </li>",
"     <li>",
"      Obsessive-compulsive disorder",
"     </li>",
"     <li>",
"      Oppositional defiant disorder",
"     </li>",
"     <li>",
"      Attention deficit hyperactivity disorder",
"     </li>",
"     <li>",
"      Schizophrenia or other conditions with psychosis as a feature",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the high degree of comorbidity and diagnostic overlap, individuals with Asperger disorder may be diagnosed with one of these disorders before or coincident with the diagnosis of Asperger disorder. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Early features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Associated conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical features that help to distinguish Asperger disorder from comorbid psychiatric conditions include the atypical social and communication skills, and normal cognitive skills (",
"    <a class=\"graphic graphic_table graphicRef80236 \" href=\"UTD.htm?6/3/6205\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Social skills'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Language skills'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other conditions that should be considered in the differential diagnosis of Asperger disorder include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/20/15689/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Expressive or mixed receptive-expressive language disorder",
"     </li>",
"     <li>",
"      Nonverbal learning disorder",
"     </li>",
"     <li>",
"      Social awkwardness related to language disorders, anxiety disorders, or attention deficit hyperactivity disorder, amongst others",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources on Asperger disorder for providers, patients, and families are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef70862 \" href=\"UTD.htm?32/27/33213\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/18/24865?source=see_link\">",
"       \"Patient information: Asperger syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hallmark of Asperger disorder is atypical social development accompanied by extreme behavioral rigidity, which is usually apparent by school age (",
"      <a class=\"graphic graphic_table graphicRef60599 \" href=\"UTD.htm?12/57/13212\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early features may include delayed use of gestures, joint attention, and pointing and referring to an object of interest, but these may escape notice because of normal language and cognitive development. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Early features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of atypical social development include failure to respect personal boundaries, one-sided conversations about a preferred topic of interest, disregarding the level of interest of the listener, lack of interest in or effort to join in activities of other children, abnormal gaze (avoidant or overly intense), and abnormal facial expressions (invariant or exaggerated). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Social skills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with Asperger disorder have normal vocabulary and grammar skills, but abnormal prosody and pragmatics (functional and social use of language). They understand language literally and have difficulty understanding that meaning may change with context. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Language skills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Behavioral features of Asperger disorder include repetitive and perseverative interests, inflexibility, disorganization, difficulty completing chores or daily tasks, anxiety, disruptive behaviors, executive dysfunction, and sensory sensitivity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Behavioral features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychiatric problems that are associated with Asperger disorder include anxiety disorder, oppositional defiant disorder, attention deficit hyperactivity disorder, depression, and other mood disorders. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of children with suspected Asperger disorder is most effectively conducted by a multidisciplinary team. The central objective is to establish a comprehensive, detailed profile of the child's strengths, weaknesses, and challenges. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The multidisciplinary evaluation should include a history of the child's early development, current symptoms, speech and language evaluation, and neuropsychologic testing to differentiate Asperger disorder from other conditions in the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef80236 \" href=\"UTD.htm?6/3/6205\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Multidisciplinary evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gold standard for making a diagnosis of Asperger disorder combines clinical judgment (ie, identification of the clinical features using history and clinical observations) and a formal diagnostic interview (ie, using a diagnostic tool for autism or Asperger disorder). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th ed, American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/2\">",
"      Klin A, Volkmar FR. Asperger syndrome: diagnosis and external validity. Child Adolesc Psychiatr Clin N Am 2003; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/3\">",
"      Tantam D, Girgis S. Recognition and treatment of Asperger syndrome in the community. Br Med Bull 2009; 89:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/4\">",
"      Macintosh KE, Dissanayake C. Annotation: The similarities and differences between autistic disorder and Asperger's disorder: a review of the empirical evidence. J Child Psychol Psychiatry 2004; 45:421.",
"     </a>",
"    </li>",
"    <li>",
"     Pervasive Developmental Disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;). American Psychiatric Association, Washington, DC, 2000. p. 70.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/6\">",
"      Johnson CP, Myers SM, American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Mental Health. Autism spectrum disorders (pervasive developmental disorders). file://www.nimh.nih.gov/health/publications/autism/complete-index.shtml (Accessed on August 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/8\">",
"      Woodbury-Smith MR, Volkmar FR. Asperger syndrome. Eur Child Adolesc Psychiatry 2009; 18:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/9\">",
"      Gillberg IC, Gillberg C. Asperger syndrome--some epidemiological considerations: a research note. J Child Psychol Psychiatry 1989; 30:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/10\">",
"      Gillberg C. Asperger syndrome in 23 Swedish children. Dev Med Child Neurol 1989; 31:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/11\">",
"      Ehlers S, Gillberg C. The epidemiology of Asperger syndrome. A total population study. J Child Psychol Psychiatry 1993; 34:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/12\">",
"      Ellefsen A, Kampmann H, Billstedt E, et al. Autism in the Faroe Islands: an epidemiological study. J Autism Dev Disord 2007; 37:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/13\">",
"      Fombonne E, Tidmarsh L. Epidemiologic data on Asperger disorder. Child Adolesc Psychiatr Clin N Am 2003; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/14\">",
"      Gillberg C, Wing L. Autism: not an extremely rare disorder. Acta Psychiatr Scand 1999; 99:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/15\">",
"      Kopra K, von Wendt L, Nieminen-von Wendt T, Paavonen EJ. Comparison of diagnostic methods for asperger syndrome. J Autism Dev Disord 2008; 38:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/16\">",
"      Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/17\">",
"      Fombonne, E. The Changing Epidemiology of Autism. J Appl Res Intellect Disabil 2005; 18:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/18\">",
"      Ghaziuddin M. A family history study of Asperger syndrome. J Autism Dev Disord 2005; 35:177.",
"     </a>",
"    </li>",
"    <li>",
"     Susceptibility to Asperger syndrome. In: Online Mendelian Inheritance in Man. Available at: www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=608638. (Accessed on August 16, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/20\">",
"      Rinehart NJ, Bradshaw JL, Brereton AV, Tonge BJ. A clinical and neurobehavioural review of high-functioning autism and Asperger's disorder. Aust N Z J Psychiatry 2002; 36:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/21\">",
"      Kwon H, Ow AW, Pedatella KE, et al. Voxel-based morphometry elucidates structural neuroanatomy of high-functioning autism and Asperger syndrome. Dev Med Child Neurol 2004; 46:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/22\">",
"      McAlonan GM, Suckling J, Wong N, et al. Distinct patterns of grey matter abnormality in high-functioning autism and Asperger's syndrome. J Child Psychol Psychiatry 2008; 49:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/23\">",
"      Howlin P, Asgharian A. The diagnosis of autism and Asperger syndrome: findings from a survey of 770 families. Dev Med Child Neurol 1999; 41:834.",
"     </a>",
"    </li>",
"    <li>",
"     Asperger's disorder. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;), American Psychiatric Association, Arlington, VA, 2000. p.80.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/25\">",
"      McConachie H, Le Couteur A, Honey E. Can a diagnosis of Asperger syndrome be made in very young children with suspected autism spectrum disorder? J Autism Dev Disord 2005; 35:167.",
"     </a>",
"    </li>",
"    <li>",
"     Volkmar, FR, Klin, A. Diagnostic issues in Asperger syndrome. In: Asperger syndrome, The Guilford Press, New York 2000. p.25.",
"    </li>",
"    <li>",
"     Johnson, CP, Myers, SM. Autism spectrum disorders. In: Developmental-Behavioral Pediatrics. Evidence and Practice. Wolraich, ML, Drotar, DD, Dworkin, PH, Perrin, EC (Eds), Mosby Elsevier, Philadelphia 2008. p.519.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/28\">",
"      Baron-Cohen S, Leslie AM, Frith U. Does the autistic child have a \"theory of mind\"? Cognition 1985; 21:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/29\">",
"      Hill EL, Bird CM. Executive processes in Asperger syndrome: patterns of performance in a multiple case series. Neuropsychologia 2006; 44:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/30\">",
"      Wing L. Asperger's syndrome: a clinical account. Psychol Med 1981; 11:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/31\">",
"      Ghaziuddin M, Weidmer-Mikhail E, Ghaziuddin N. Comorbidity of Asperger syndrome: a preliminary report. J Intellect Disabil Res 1998; 42 ( Pt 4):279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/32\">",
"      Yoshida Y, Uchiyama T. The clinical necessity for assessing Attention Deficit/Hyperactivity Disorder (AD/HD) symptoms in children with high-functioning Pervasive Developmental Disorder (PDD). Eur Child Adolesc Psychiatry 2004; 13:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/33\">",
"      Lee DO, Ousley OY. Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/34\">",
"      Weisbrot DM, Gadow KD, DeVincent CJ, Pomeroy J. The presentation of anxiety in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/35\">",
"      Gadow KD, Devincent CJ, Drabick DA. Oppositional defiant disorder as a clinical phenotype in children with autism spectrum disorder. J Autism Dev Disord 2008; 38:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/36\">",
"      Matson JL, Nebel-Schwalm MS. Comorbid psychopathology with autism spectrum disorder in children: an overview. Res Dev Disabil 2007; 28:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/37\">",
"      Mattila ML, Hurtig T, Haapsamo H, et al. Comorbid psychiatric disorders associated with Asperger syndrome/high-functioning autism: a community- and clinic-based study. J Autism Dev Disord 2010; 40:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/38\">",
"      White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 2009; 29:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/39\">",
"      Kuusikko S, Pollock-Wurman R, Jussila K, et al. Social anxiety in high-functioning children and adolescents with Autism and Asperger syndrome. J Autism Dev Disord 2008; 38:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/40\">",
"      Ozonoff S, Goodlin-Jones BL, Solomon M. Evidence-based assessment of autism spectrum disorders in children and adolescents. J Clin Child Adolesc Psychol 2005; 34:523.",
"     </a>",
"    </li>",
"    <li>",
"     Saulnier CA, Volkmar FR. Asperger syndrome. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn M, Zuckerman B, Caronna EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.120.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/42\">",
"      Campbell JM. Diagnostic assessment of Asperger's disorder: a review of five third-party rating scales. J Autism Dev Disord 2005; 35:25.",
"     </a>",
"    </li>",
"    <li>",
"     Asperger's disorder. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;). American Psychiatric Association, Arlington, VA 2000. p.80.",
"    </li>",
"    <li>",
"     World Health Orgnaization. The ICD-10 classification of mental and behavioral disorders. Geneva 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/45\">",
"      Szatmari P, Bremner R, Nagy J. Asperger's syndrome: a review of clinical features. Can J Psychiatry 1989; 34:554.",
"     </a>",
"    </li>",
"    <li>",
"     First, MB. Mutually Exclusive versus Co-Occurring Diagnostic Categories: The Challenge of Diagnostic Comorbidity. Clinical Psychiatry, Columbia University College of Physicians and Surgeons, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/47\">",
"      Clark T, Feehan C, Tinline C, Vostanis P. Autistic symptoms in children with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry 1999; 8:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/48\">",
"      Ivarsson T, Melin K. Autism spectrum traits in children and adolescents with obsessive-compulsive disorder (OCD). J Anxiety Disord 2008; 22:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/49\">",
"      Mayes SD, Calhoun SL, Crites DL. Does DSM-IV Asperger's disorder exist? J Abnorm Child Psychol 2001; 29:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/50\">",
"      Volkmar FR, Klin A, Pauls D. Nosological and genetic aspects of Asperger syndrome. J Autism Dev Disord 1998; 28:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/51\">",
"      Klin A, Pauls D, Schultz R, Volkmar F. Three diagnostic approaches to Asperger syndrome: implications for research. J Autism Dev Disord 2005; 35:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/52\">",
"      Szatmari P, Bryson S, Duku E, et al. Similar developmental trajectories in autism and Asperger syndrome: from early childhood to adolescence. J Child Psychol Psychiatry 2009; 50:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/53\">",
"      Kamp-Becker I, Smidt J, Ghahreman M, et al. Categorical and dimensional structure of autism spectrum disorders: the nosologic validity of Asperger Syndrome. J Autism Dev Disord 2010; 40:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/54\">",
"      Woodbury-Smith M, Klin A, Volkmar F. Asperger's syndrome: a comparison of clinical diagnoses and those made according to the ICD-10 and DSM-IV. J Autism Dev Disord 2005; 35:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/55\">",
"      Thede LL, Coolidge FL. Psychological and neurobehavioral comparisons of children with Asperger's Disorder versus High-Functioning Autism. J Autism Dev Disord 2007; 37:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/56\">",
"      Noterdaeme M, Wriedt E, H&ouml;hne C. Asperger's syndrome and high-functioning autism: language, motor and cognitive profiles. Eur Child Adolesc Psychiatry 2010; 19:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/20/15689/abstract/57\">",
"      Hartley SL, Sikora DM. Which DSM-IV-TR criteria best differentiate high-functioning autism spectrum disorder from ADHD and anxiety disorders in older children? Autism 2009; 13:485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 604 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15689=[""].join("\n");
var outline_f15_20_15689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Early features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Social skills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Language skills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Behavioral features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clumsiness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      School performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Role of the primary care provider",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Multidisciplinary evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Within autism spectrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/604\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/604|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/57/13212\" title=\"table 1\">",
"      DSM IV criteria Asperger disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/6/29804\" title=\"table 2\">",
"      DSM IV criteria autism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/36/30285\" title=\"table 3\">",
"      Asperger disorder scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/3/6205\" title=\"table 4\">",
"      Asperger disorder DDx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/27/33213\" title=\"table 5\">",
"      Asperger resources",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=related_link\">",
"      Asperger disorder: Management and prognosis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/18/24865?source=related_link\">",
"      Patient information: Asperger syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14361?source=related_link\">",
"      Screening tools for autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_20_15690="Treatment of anaphylaxis during pregnancy";
var content_f15_20_15690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F87184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F87184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Treatment of anaphylaxis during pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 641px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Treatment of anaphylaxis during pregnancy. This involves prompt intramuscular injection of 0.3 mg (0.3 mL) of epinephrine using a 1 mg/mL (1:1000) dilution; high-flow supplemental oxygen; the mother positioned on her left side to improve venous return to the heart; maintenance of a minimum systolic blood pressure of 90 mmHg for adequate placental perfusion; continuous electronic monitoring; cardiopulmonary resuscitation when indicated; and emergency cesarean delivery when indicated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Simons FER, Schatz M. Anaphylaxis during pregnancy. J Allergy Clin Immunol 2012; 130:597. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15690=[""].join("\n");
var outline_f15_20_15690=null;
var title_f15_20_15691="Serologic findings in LGL";
var content_f15_20_15691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Serologic findings in CD3+ large granular lymphocyte leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Freqeuncy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid factor",
"       </td>",
"       <td>",
"        60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antinuclear antibody",
"       </td>",
"       <td>",
"        40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyclonal hypergammaglobulinemia",
"       </td>",
"       <td>",
"        10 - 40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monoclonal gammopathy",
"       </td>",
"       <td>",
"        8 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Circulating immune complexes",
"       </td>",
"       <td>",
"        55 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antineutrophil antibody",
"       </td>",
"       <td>",
"        40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive Coombs' test",
"       </td>",
"       <td>",
"        15 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from Cancer Control: Journal of the Moffitt Cancer Center. Lamy, T, Loughran, TP Jr. Large granular lymphocyte leukemia. Cancer Control 1998; 5:25.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15691=[""].join("\n");
var outline_f15_20_15691=null;
var title_f15_20_15692="Infectious cough worldwide";
var content_f15_20_15692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious considerations for chronic cough, by region",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       North America",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Eastern: blastomycosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Central: blastomycosis; histoplasmosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Western: coccidioidomycosis; echinococcosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Central and South America",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis (epidemic in Brazil, consider anywhere)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blastomycosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coccidioidomycosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paracoccidioidomycosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Echinococcosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paragonimiasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Europe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis (epidemic in Eastern Europe, consider anywhere)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Echinococcosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Africa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis (epidemic)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blastomycosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paragonimiasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Echinococcosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Asia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis (epidemic in many areas)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blastomycosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Echinococcosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paragonimiasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Australia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Echinococcosis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15692=[""].join("\n");
var outline_f15_20_15692=null;
var title_f15_20_15693="Anthrax vaccine target groups";
var content_f15_20_15693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for use of anthrax vaccine absorbed, by type of population",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pre-event*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Postexposure prophylaxis (PEP)",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         General public",
"        </strong>",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Special populations in the general public",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pregnant women",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breastfeeding women",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children (aged &lt;18 yrs)",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"       <td>",
"        Determined on an event-by-event basis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medical professionals",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Populations at risk for occupational exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persons who handle animals or animal products",
"       </td>",
"       <td>",
"        Not routinely recommended&Delta;",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persons who perform certain types of laboratory work",
"       </td>",
"       <td>",
"        Recommended&loz;",
"       </td>",
"       <td>",
"        Based on pre-event vaccination status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persons who work in postal facilities",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Military personnel",
"       </td>",
"       <td>",
"        As recommended by the Department of Defense",
"       </td>",
"       <td>",
"        As recommended by the Department of Defense",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persons involved in environmental investigations or remediation efforts",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Based on pre-event vaccination status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persons involved in emergency response activities&sect;",
"       </td>",
"       <td>",
"        Not routinely recommended; may be offered on a voluntary basis under the direction of a comprehensive occupational health and safety program",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Five 0.5-mL doses administered intramuscularly at 0 wks, 4 wks, 6 mos, 12 mos, and 18 mos; annual boosters are required to maintain immunity.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Three 0.5-mL doses administered subcutaneously at 0, 2, and 4 wks after exposure to aerosolized",
"      <em>",
"       Bacillus anthracis",
"      </em>",
"      spores for persons who have not completed the pre-event vaccination schedule.",
"      <br>",
"       &Delta; Recommended only if handling potentially infected animals in research settings or in areas with a high incidence of enzootic anthrax or when standards and restrictions are insufficient to prevent exposure to",
"       <em>",
"        B. anthracis",
"       </em>",
"       spores.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Laboratorians who work 1) with pure cultures of",
"        <em>",
"         B. anthracis",
"        </em>",
"        or preparations of",
"        <em>",
"         B. anthracis",
"        </em>",
"        spores, 2) with environmental samples associated with anthrax investigations, or 3) in spore-contaminated areas or other settings with exposure to aerosolized",
"        <em>",
"         B. anthracis",
"        </em>",
"        spores. Laboratorians who do not work in these settings are not recommended for pre-event vaccine.",
"        <br>",
"         &sect; Persons involved in emergency response activities might include persons who work in police departments, fire departments, hazardous material units, and the National Guard, as well as other government responders. These persons might perform site investigations, respond to suspicious substance reports (also known as white powder incidents), and perform other related activities, such as evacuation procedures or other activities critical to the maintenance of infrastructure.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010; 59(RR-6):1-36.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15693=[""].join("\n");
var outline_f15_20_15693=null;
var title_f15_20_15694="Amyloid precursor proteins I";
var content_f15_20_15694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70058%7ERHEUM%2F81283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70058%7ERHEUM%2F81283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protein precursor of amyloid deposits-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Protein class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precursor protein (abbreviation)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amyloid type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        High density apolipoproteins",
"       </td>",
"       <td>",
"        (Apo) serum AA",
"       </td>",
"       <td>",
"        AA",
"       </td>",
"       <td>",
"        Associated with amyloid complicating chronic infections or inflammatory diseases, and some heredofamilial periodic fever syndromes, such as FMF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apolipoprotein A-I (ApoAI)",
"       </td>",
"       <td>",
"        AApoAI",
"       </td>",
"       <td>",
"        Age-related amyloid occurring in the aortic intima, and some hereditary neuropathic or cardiopathic amyloidoses",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apolipoprotein A-II (ApoAII)",
"       </td>",
"       <td>",
"        AApoAII",
"       </td>",
"       <td>",
"        Some hereditary nephropathic amyloidoses",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Immunoglobulin (Ig) gene superfamily",
"       </td>",
"       <td>",
"        Ig L chain/Ig H chains (IgL/IgH)",
"       </td>",
"       <td>",
"        AL/AH",
"       </td>",
"       <td>",
"        Primary and myeloma-associated amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta-2 microglobulin",
"       </td>",
"       <td>",
"        A&beta;2m",
"       </td>",
"       <td>",
"        Dialysis amyloidosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Neuroendocrine",
"       </td>",
"       <td>",
"        (Pro)Calcitonin",
"       </td>",
"       <td>",
"        ACal",
"       </td>",
"       <td>",
"        Amyloid complicating C-cell thyroid tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Islet amyloid",
"       </td>",
"       <td>",
"        AIAPP",
"       </td>",
"       <td>",
"        Islet cell amyloid in Insulinomas, type II diabetes mellitus, and aging",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial natriuretic peptide",
"       </td>",
"       <td>",
"        AANF",
"       </td>",
"       <td>",
"        Isolated atrial amyloidosis of aging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolactin/Apro",
"       </td>",
"       <td>",
"        APro",
"       </td>",
"       <td>",
"        Prolactinomas/aging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin",
"       </td>",
"       <td>",
"        Alns",
"       </td>",
"       <td>",
"        Local amyloid complicating use of the insulin pump",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Cytoskeleton-related",
"       </td>",
"       <td>",
"        Gelsolin",
"       </td>",
"       <td>",
"        AGel",
"       </td>",
"       <td>",
"        Hereditary neuropathic amyloid associated with corneal lattice dystrophy and cutis laxa (Meretoja syndrome)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratin",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        Cutaneous amyloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratoepithelin",
"       </td>",
"       <td>",
"        AKer",
"       </td>",
"       <td>",
"        Hereditary granular, lattice, and avellino corneal dystrophies",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Does not yet have nomenclature designated.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Mucchiano GI, Haggqvist B, Sletten K, Westermark P, J Pathol 2001; 193:270.",
"       </li>",
"       <li>",
"        de Sousa MM, Vital C, Ostler D, et al, Am J Pathol 2000; 156:1911.",
"       </li>",
"       <li>",
"        Benson MD, Liepnieks JJ, Yazaki M, et al, Genomics 2001; 72:272.",
"       </li>",
"       <li>",
"        Hoppener JW, Ahren B, Lips CJ. N Engl J Med 2000; 343:411.",
"       </li>",
"       <li>",
"        Kiuru S, Amyloid 1998; 5:55.",
"       </li>",
"       <li>",
"        Klintworth GK. Front Biosci 2003; 8:d687.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protein precursor of amyloid deposits-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Protein class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precursor protein (abbreviation)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amyloid type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transport protein",
"       </td>",
"       <td>",
"        Transthyretin (TTR; prealbumin)",
"       </td>",
"       <td>",
"        ATTR",
"       </td>",
"       <td>",
"        Hereditary neuropathic and/or cardiopathic amyloids; vitreous amyloidosis; leptomeningeal or renal amyloid in some kindreds; senile systemic amyloidosis",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Cerebrovascular/ neurdegeneration",
"       </td>",
"       <td>",
"        Amyloid precursor protein (APP)",
"       </td>",
"       <td>",
"        ABeta",
"       </td>",
"       <td>",
"        Hereditary and sporadic Alzheimer disease; congophilic cerebral angiopathy",
"        <sup>",
"         [2,3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prion protein (PRP)",
"       </td>",
"       <td>",
"        APrPsc",
"       </td>",
"       <td>",
"        Hereditary and sporadic spongiform encephalopathies",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRI gene product",
"       </td>",
"       <td>",
"        ABri/ADan",
"       </td>",
"       <td>",
"        Hereditary dementias (British and Danish types)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystatin C (Cys - C)",
"       </td>",
"       <td>",
"        ACys",
"       </td>",
"       <td>",
"        Hereditary cerebrovascular hemorrhage with amyloidosis (Icelandic type)",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Coagulation protein",
"       </td>",
"       <td>",
"        Fibrinogen alpha chain",
"       </td>",
"       <td>",
"        AFib",
"       </td>",
"       <td>",
"        Hereditary nephropathic amyloidosis",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Enzyme",
"       </td>",
"       <td>",
"        Lysozome",
"       </td>",
"       <td>",
"        ALys",
"       </td>",
"       <td>",
"        Hereditary nephropathic amyloidosis; may have marked hepatic, splenic and gastrointestinal amyloid deposits",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Other",
"       </td>",
"       <td>",
"        Keratoepithelin",
"       </td>",
"       <td>",
"        AKer",
"       </td>",
"       <td>",
"        Various familial corneal dystrophies",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactoferrin",
"       </td>",
"       <td>",
"        ALac",
"       </td>",
"       <td>",
"        Corneal amyloidosis associated with trichiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Odontogenic ameloblast-associated protein",
"       </td>",
"       <td>",
"        AOaap",
"       </td>",
"       <td>",
"        Calcifying epithelial odontogenic tumors (CEOTs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semenogelin 1",
"       </td>",
"       <td>",
"        ASem1",
"       </td>",
"       <td>",
"        Senile seminal vesicle amyloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactadherin",
"       </td>",
"       <td>",
"        AMed",
"       </td>",
"       <td>",
"        Senile aortic amyloid; media deposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocyte chemotactic factor 2",
"       </td>",
"       <td>",
"        ALect2",
"       </td>",
"       <td>",
"        Amyloid nephropathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Connors LH, Lom A, Prokaeva T, et al. Amyloid 2003; 10:160 (TTR variants updated at file://medicine.bu.edu/amyloid/Amyloidl.htm).",
"      </li>",
"      <li>",
"       Selkoe DJ. Physiol Revs 2001; 81:741.",
"      </li>",
"      <li>",
"       Revesz T, Ghiso J, Lashley T, et al. J Neuropathol Exp Neurol 2003; 62:885.",
"      </li>",
"      <li>",
"       Prusiner SB. N Engl J Med 2001; 344:1516.",
"      </li>",
"      <li>",
"       Vidal R, Frangione B, Rostagno A, et al. Nature 1999; 399:776 and Gibson G, Gunasekera N, Lee M, et al. J Neurochem 2004; 88:281.",
"      </li>",
"      <li>",
"       Olafsson I, Grubb A. Amyloid 2000; 7:70.",
"      </li>",
"      <li>",
"       Hawkins PN. J Nephrol 2003; 16:443.",
"      </li>",
"      <li>",
"       Klintworth GK. Front Biosci 2003; 8:d687.",
"      </li>",
"      <li>",
"       Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid 2010; 17:101.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15694=[""].join("\n");
var outline_f15_20_15694=null;
var title_f15_20_15695="Complete CBD transection I";
var content_f15_20_15695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete transection of the common bile duct after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP demonstrating complete transection of the common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_20_15695=[""].join("\n");
var outline_f15_20_15695=null;
